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ABSTRACT: Synthesis and antimalarial activity of 94 novel bipyrrole tambjamines
(TAs) and a library of B-ring functionalized tripyrrole prodiginines (PGs) against a
panel of Plasmodium falciparum strains are described. The activity and structure−activity
relationships demonstrate that the ring-C of PGs can be replaced by an alkylamine,
providing for TAs with retained/enhanced potency. Furthermore, ring-B of PGs/TAs
can be substituted with short alkyl substitutions at either 4-position (replacement of
OMe) or 3- and 4-positions without impacting potency. Eight representative TAs and
two PGs have been evaluated for antimalarial activity against multidrug-resistant P. yoelii
in mice in the dose range of 5−100 mg/kg × 4 days by oral administration. The
KAR425 TA oﬀered greater eﬃcacy than previously observed for any PG, providing
100% protection to malaria-infected mice until day 28 at doses of 25 and 50 mg/kg ×
4 days, and was also curative in this model in a single oral dose (80 mg/kg). This study
presents the ﬁrst account of antimalarial activity in tambjamines.
■ INTRODUCTION
Malaria is a global parasitic infectious disease caused by Plasmodium
parasites, among which Plasmodium falciparum (Pf) is the most
dangerous one, with the highest rates of complications and
mortality. It has been estimated that 584 000 people died from
this disease in 2013, and the burden is heaviest in the African
region, where an estimated 90% of all malaria deaths occur, and
in children aged under 5 years, who account for 78% of all
deaths.1 On the heels of the global spread of chloroquine-
resistant P. falciparum (CQRPf), resistance has also quickly
developed to a variety of quinoline analogues, to antifolates, to
inhibitors of electron transport, and perhaps most ominously,
now to artemisinin.2,3 Therefore, novel medicinal agents are urgently
needed to overcome the emergence and spread of resistance.
Prodiginines (PGs, 1a−c), tambjamines (TAs, 2a−b), and
modiﬁed prodiginines (streptorubin B (3a), metacycloprodigi-
nine (3b), and marineosins (4 and 5)) belong to a family of
pyrrolylpyrromethene (PPM) alkaloids (Figure 1) derived from
bacterial and marine sources.4−7 These structurally distinctive
natural products can be envisioned to arise via a bifurcated
process from a common precursor, 4-methoxy-2,2′-bipyrrole-5-
carboxaldehyde (MBC; 6, Figure 1), and the corresponding
alkylpyrrole and/or alkylamine.7−10 The natural and synthetic
PPM products are undergoing intense scrutiny in the medicinal
chemistry because of both their wide range of biological
activities and modes of action (antimicrobial,11−14 immuno-
suppressive,15−22 antitumor,11,12,23 anticancer,6,24−30 antimalar-
ial,7,31−38 transmembrane anion transport,28−30,39−45 and DNA
intercalation46,47). Certain PGs and TAs have also been
observed to bind duplex DNA and can cleave this biomolecule
in the presence of Cu(II).4,48 Some of these compounds have
shown clinical potential, and in particular, PG analogue GX15-
070 has completed phase II clinical trials for the treatment of
small cell lung cancer and is engaged in multiple clinical trials
for the treatment of other cancer conditions.49,50
As a part of an ongoing interest in developing new anti-
parasitic agents, we reisolated the natural PGs 1a and 3a from
Streptomyces coelicolor M511, and 3b from S. longisporusruber
(Figure 1).51,52 These natural PGs exhibited great potency with
very low IC50 values against P. falciparum strains, a potency only
slightly more than chloroquine (CQ).37 The natural PG 3b
provided an excellent in vivo eﬃcacy against multidrug-resistant
P. yoelii in mice by oral route, and it was curative in this model
at 100 mg kg−1 day−1, and three of four mice were cured. These
data provided the ﬁrst demonstration of oral eﬀectiveness of
PGs.37 Recently we also have isolated the modiﬁed prodiginines,
marineosins (5), and their pathway intermediates 23-hydroxy-
undecylprodiginine (1b), 23-ketoundecylprodiginine (1c), and
premarineosin (4) through heterologous expression of the entire mar
gene cluster and/or gene replacement mutants in a heterologous
host, S. venezuelae.7 Of these, the compound 4 antimalarial
activity compares favorably with the most potent naturally
occurring PGs and CQ.
The structural and functional diversity and promising
antimalarial activity of these natural PGs and marineosins
spurred us to synthesize various analogues of these lead mole-
cules to obtain more active compounds. We recently reported
the antimalarial activity of a large library of synthetic PGs.37,38
This work has shown that a terminal nonalkylated pyrrole
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(ring-A) and 3,5-dialkyl substitutions on the other terminal
alkylated pyrrole (ring-C) of a natural tripyrrole PGs core
structure are crucial for the potent antimalarial activity.
A number of the synthetic PGs were eﬀective at lower
concentrations (IC50 = 0.9−16.0 nM) against P. falciparum
strains, and their potency was more than the natural PGs and
CQ. However, preliminary in vitro assays indicate concerns
associated with the toxicity of PGs.
Our work on the potent antimalarial activity of PGs37,38 to
date has been limited to SAR studies of A- and C-ring
functionalized PGs. With a few exceptions,20,24,25,30,38 there
have been no reports of a comprehensive series of TAs and
B-ring functionalized PGs being prepared and evaluated for
biological activities. In particular, the antimalarial activities of
the TAs have not been reported to the best of our knowledge.
These toxicity concerns for PGs and the intriguing biological
activities of these PPM scaﬀolds have spurred us to expand the
structural and functional diversity. Therefore, we have under-
taken syntheses of novel TAs and B-ring functionalized PGs for
enhanced antimalarial activity and reduced toxicity. To that
end, we have developed new methods for the synthesis of
various 2,2′-bipyrrole-5-carboxaldehydes53 and utilized in the
generation of the novel TAs and B-ring functionalized PGs.
Here we report the synthesis and structure−activity relation-
ships (SARs) of TAs and B-ring functionalized PGs. The results
show TAs with impressive in vitro potency and low toxicity and
demonstrate that a tripyrrole structure is not required for
activity. Furthermore, evidence of in vivo eﬃcacy with TAs,
including curative eﬃcacy in mice after oral administration, is
reported.
■ RESULTS AND DISCUSSION
Chemistry. The key precursors 6−43, which are involved in
the synthesis of prodiginines (PGs) and tambjamines (TAs)
(Scheme 10), are depicted in Figures 2 and 3. By use of
literature methodologies, MBC (6) and analogue 21 were
prepared from readily available 4-methoxy-3-pyrrolin-2-one
in two steps54 and 2,2′-bipyrrole-5-carboxaldehydes 7, 8, and
10−18 were synthesized by our recent methods.53 The
syntheses of various new pyrrole carboxaldehydes 9, 19, 20,
and 22−39 are outlined in Schemes 1−9.
Synthesis of 4-(4-Chlorophenyl)-[2,2′-bipyrrole]-5-
carboxaldehyde (9). Synthesis of the aryl substituted
3-pyrrolin-2-one 48, a key synthon in the synthesis of bipyrrole-
carboxaldehyde 9, began with the coupling of Boc-glycine (44)
with 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid) to
aﬀord the acylated Meldrum’s acid, which was further con-
verted into the desired intermediate 45 by an intramolecular
cyclization and a subsequent decarboxylation (Scheme 1).55
The compound 45 was treated with p-toluenesulfonyl chloride
in the presence of N,N-diisopropylethylamine (DIPEA) to give
the tosylated product 46, in 89% yield, which was further sub-
jected to Suzuki coupling reaction with 4-chlorophenylboronic
acid to give the N-Boc-4-aryl-3-pyrrolin-2-one 47. The desired
4-aryl-3-pyrrolin-2-one 48 was obtained in excellent yield by
deprotection of the N-Boc group of 47 with triﬂuoroacetic
acid.56 By use of the reported Vilsmeier formylation method,54
48 was then smoothly transformed to 5-bromo-3-(4-chlorophenyl)-
pyrrole-2-carboxaldehyde 49, which when further subjected to
Suzuki coupling with N-Boc-2-pyrroleboronic acid followed by
deprotection of the N-Boc group gave the desired 2,2′-
bipyrrole-5-carboxaldehyde 9 in 59% yield (Scheme 1).53
Synthesis of 2,2′-Bipyrrole-5-carboxaldehyde (19). In
1988, Borger and Patel synthesized the 2,2′-bipyrrole-5-
carboxaldehyde (19) in seven steps.12 In this work, we suc-
cessfully accomplished 19 in two one-pot sequences from easily
available pyrrole (50), as shown in Scheme 2. To that end,
compound 50 was consecutively treated with N-chlorosuccini-
mide (NCS) and Vilsmeier reagent (POCl3/DMF, in situ generation)
under controlled temperatures to obtain the 5-chloro-pyrrole-2-
carboxaldehyde (51) in good yield.57 The Suzuki cross-coupling
of 51 with N-Boc-2-pyrroleboronic acid followed by deprotection
of the N-Boc group provided the desired bipyrrolecarboxaldehyde
19 in 45% isolated yield (Scheme 2).
Synthesis of 3-(Pyrrol-2-yl)-4,5,6,7-tetrahydroisoin-
dole-1-carboxaldehyde (20). The key intermediate 53 was
prepared via BartoneZard’s method, using 1-nitro-1-cyclo-
hexene (52) as a starting material (Scheme 3).53,58,59 Upon
treatment with NaOH in ethylene glycol under reﬂux, 53 was
Figure 1. Structures of PPM natural products (1−5) and their common biosynthetic precursor (6).
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smoothly converted to 4,5,6,7-tetrahydroisoindole (54) in
90% yield by successive hydrolysis and decarboxylation of
the ester group.53 Using the standard Vilsmeier formylation
method, 54 was then transformed to 4,5,6,7-tetrahydroisoin-
dole-1-carboxaldehyde (55), which when further treated
with 1,3-dibromo-5,5-dimethylhydantoin (DBDMH)53 in THF
at −78 °C to room temperature provided the 3-bromo-4,5,6,
7-tetrahydroisoindole-1-carboxaldehyde (56). Subsequently,
Suzuki cross-coupling reaction between 56 and N-Boc-2-
pyrroleboronic acid and further deprotection of the N-Boc
group led to the desired bipyrrolecarboxaldehyde 20 in good
yield (Scheme 3).
Synthesis of Isomeric [2,3′-Bipyrrole]-5′-carboxalde-
hydes (22−25). To investigate the ring-A positional eﬀect on
antimalarial activity, the isomeric bipyrrolecarboxaldehydes
22−25 were prepared, as shown in Scheme 4. Pyrrole-2-
carboxaldehyde (40) and 3,5-dimethylpyrrole-2-carboxaldehyde
(42) were obtained from commercial sources, and the 3-
methylpyrrole-2-carboxaldehyde (57) and 3-ethylpyrrole-2-
carboxaldehyde (58) were prepared according to our reported
procedures.53 These pyrrole-2-carboxaldehydes were then
converted into the corresponding 4-bromopyrrole-2-carbox-
aldehydes 59−62 via a regioselective bromination at 4-position
using DBDMH in THF in good yields (Scheme 4).53 These
Figure 2. Key precursors (6−20) for the synthesis of B-ring functionalized PGs and TAs.
Figure 3. Key precursors (21−43) for the synthesis of A- and B-ring functionalized PGs and TAs.
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Scheme 1. Synthesis of 4-(4-Chlorophenyl)-[2,2′-bipyrrole]-5-carboxaldehyde (9)
Scheme 2. Synthesis of 2,2′-Bipyrrole-5-carboxaldehyde (19)
Scheme 3. Synthesis of 3-(Pyrrol-2-yl)-4,5,6,7-tetrahydroisoindole-1-carboxaldehyde (20)
Scheme 4. Synthesis of Isomeric [2,3′-Bipyrrole]-5′-carboxaldehydes (22−25)
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4-bromopyrrole-2-carboxaldehydes 59−62 were further sub-
jected to Suzuki coupling reaction with N-Boc-2-pyrroleboronic
acid, and a subsequent treatment with LiOH in THF/MeOH
(1:1) at 60 °C resulted in the desired isomeric bipyrrole-
caraboxaldehydes 22−25 (Scheme 4).
Synthesis of MBC’s Analogues (26−31) Containing
Herteroaryl/Aryl Groups in the Place of Ring-A. To probe
the exact role of the 2-pyrrolyl moiety (ring-A) on activity, we
have prepared various key carboxaldehyde precursors 26−31 in
which the ring-A is completely replaced by various heterocycles
and/or aryl moieties and the ring-B is substituted with short
alkyl groups (Scheme 5). The 5-bromo-3,4-dimethylpyrrole-2-
carboxaldehyde (65) was prepared in six steps according to the
literature methods from acetaldehyde (63) and nitroethane
(64),53 and it was subsequently subjected to Suzuki coupling
reaction with various boronic acids, and further deprotection of
the Boc/TIPS group led to the corresponding carboxaldehydes
26−31 (Scheme 5).
Synthesis of 3,4-Dimethyl-[2,2′-bipyrrole]-5-carboxal-
dehydes Where Ring-A Contains C-Alkyl Groups (32−36).
To investigate the eﬀect of the ring-A alkyl substituents pattern
on potency, we have prepared various alkylated bipyrrole-
carboxaldehyde precursors 32−36, as shown in Schemes 6 and 7.
The 2-acetylpyrrole (66a), 2,4-dimethylpyrrole (67c), and
3-ethyl-2,4-dimethylpyrrole (67d) were obtained from com-
mercial sources, and the 2-isobutyrylpyrrole (66b) was pre-
pared according to the literature methods.60 The compounds
66a and 66b were then converted into the corresponding
2-alkylpyrroles 67a and 67b, respectively, using LiAlH4 in THF
under reﬂux (Scheme 6).61 By use of standard procedures, the
N-Boc-protected pyrroles 68a−d were prepared in excellent
yields from 67a−d using di-tert-butyl dicarbonate (Boc2O) in
Scheme 5. Synthesis of MBC’s analogues containing heteroaryl/aryl groups in the place of ring-A (26−31)
Scheme 6. Synthesis of 3,4-Dimethyl-[2,2′-bipyrrole]-5-carboxaldehydes Where the Ring-A Contains C-Alkyl Groups (32−35)
Scheme 7. Synthesis of 4′-Ethyl-3,4-dimethyl-[2,2′-bipyrrole]-5-carboxaldehyde (36)
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the presence of 4-dimethylaminopyridine (DMAP), and sub-
sequently these were converted into the corresponding 5-alkyl-
(1-tert-butoxycarbonylpyrrol-2-yl)boronic acids 69a−d.62 The
resultant boronic acids 69a−d were carried forward into the
Suzuki coupling reaction with 65 without further puriﬁcation to
aﬀord their corresponding [2,2′-bipyrrole]-5-carboxaldehydes
32−35 in good yields (Scheme 6).
We have also developed a simple and convenient method for
the synthesis of N-Boc-4-ethyl-2-pyrrolboronic acid (71) via a
regioselective boronylation of N-Boc-3-ethylpyrrole (70),53
using n-BuLi/2,2,6,6-tetramethylpiperidine and trimethyl bo-
rate (Scheme 7, Experimental Section). Further investigations
to expand the substrate scope of the regioselective boronylation
as well as mechanistic studies are underway in our laboratory.
Finally the 4′-ethyl-3,4-dimethyl-[2,2′-bipyrrole]-5-carboxalde-
hyde (36) was prepared in good yield via Suzuki coupling of 65
with boronic acid 71, followed by the deprotection of N-Boc
group with LiOH (Scheme 7). The ﬁnal compound 36 was fully
characterized by extensive 2D NMR analysis (see Supporting
Information).
Synthesis of 3-(Imidazol-2-yl)-4,5,6,7-tetrahydroisoin-
dole-1-carboxaldehyde (37). To investigate the role of ring-A
with an extra nitrogen atom on potency, we have replaced the
ring-A by imidazole moiety, as in 37 (Scheme 8). The N-Boc-
pyrrole 72 was prepared in 95% yield from compound 55 using
Boc2O/DMAP, and subsequently the aldehyde group was
protected by trimethyl orthoformate under acidic conditions to
obtain the desired intermediate 73. The compound 73 was
further reacted with triisopropyl borate/LDA in THF and
followed by aqueous solution of KHSO4/NH4Cl at room
temperature to provide the desired boronic acid 74 in excellent
yield.53 Finally, the Suzuki cross-coupling reaction between 74
and 2-bromoimidazole (75) and subsequent deprotection of
the N-Boc group led to the desired carboxaldehyde 37 in 65%
isolated yield (Scheme 8).
Synthesis of 3-Methyl-4,5,6,7-tetrahydroisoindole-1-
carboxaldehyde (38) and 5,5′-Methylenebis(4-ethyl-3-
methylpyrrole-2-carboxaldehyde) (39). We wanted to
study the analogues of TAs without ring-A; therefore, two rep-
resentative pyrrole aldehydes 38 and 39 (Scheme 9) were
synthesized. Initially, 1-methyl-4,5,6,7-tetrahydroisoindole (77)
was synthesized from ethyl-4,5,6,7-tetrahydroisoindole-1-car-
boxylate (53) via an unstable intermediate 76, using LiAlH4 in
THF at 0 °C to room temperature in 85% isolated yield. The
resultant alkylpyrrole 77 was further converted to 3-methyl-
4,5,6,7-tetrahydroisoindole-1-carboxaldehyde (38) by Vilsmeier
reagent (POCl3/DMF) (Scheme 9). Conversely, the bis(3-ethyl-
4-methylpyrrol-2-yl)methane (79) was prepared from diethyl-
5,5′-methylenebis(4-ethyl-3-methyl-2-pyrrolecarboxylate) (78)
in excellent yields via a successive hydrolysis and a decarboxy-
lation of the ester groups. Further Vilsmeier formylation of 79
provided the desired dicarboxaldehyde 39 in 73% isolated yield
(Scheme 9).
Synthesis of Novel PGs (85−98) and TAs (99−187). By
use of our standardized procedures, the mono- and dialkyl/alkylaryl
pyrroles 80−84 were synthesized (Figure 4).37 The acid-catalyzed
Scheme 8. Synthesis of 3-(Imidazol-2-yl)-4,5,6,7-tetrahydroisoindole-1-carboxaldehyde (37)
Scheme 9. Synthesis of 3-Methyl-4,5,6,7-tetrahydroisoindole-1-carboxaldehyde (38) and 5,5′-Methylenebis(4-ethyl-3-
methylpyrrole-2-carboxaldehyde) (39)
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condensation of either the alkylpyrroles 80−84 or the
commercially available alkyl/arylamines with various bipyrrole-
carboxaldehydes and analogues 6−43 provided the desired
PGs 85, 86, 88−98 and TAs 99−187, respectively, in good to
excellent isolated yields (Scheme 10). The PG 85 was further
treated with MeI/NaH in DMF to provide the N,N-dimethyl
PG 87 in 85% isolated yield (Scheme 10).
Synthesis of TA-like Analogues (190, 191, and 194−196).
Distinct syntheses were designed and executed to obtain a
diﬀerent class of TA-like analogues 190, 191, and 194−196, in
which the crucial ring-B of TAs is completely replaced by an
alkylamide/amine linkage (Scheme 11). To that end, com-
pound 188 was synthesized via a standard condensation method
(EDCl/DMAP) from 44 and 1-adamantylamine in 85% yield.
Removal of the Boc group of 188 by triﬂuoroacetic acid/water
(1:1) provided the intermediate 189 in good yield,63 which was
further utilized in a condensation reaction with pyrrole-2-
carboxylic acid to furnish the desired product 190. Treatment
of 190 with LiAlH4 in THF at 0 °C to reﬂux conditions gave
the 191 in 82% isolated yield (Scheme 11). Conversely, ana-
logues 194−196 were also synthesized, as shown in Scheme 11.
The pyrrole-2-carboxaldehyde (40) was subjected to Horner−
Wadsworth−Emmons (HWE) reaction with methyl dieth-
ylphosphonoacetate in the presence of NaH to obtain the
methyl-3-(pyrrol-2-yl)acrylate (192),64,65 which when hydro-
lyzed under basic (LiOH·H2O) conditions, furnished the
2-pyrrolylacrylic acid 193. Condensation of 193 with 189 in
the presence of EDCl/DMAP led to the corresponding
condensed product 194, which was further treated with
NaBH4/NiCl2·6H2O to give the saturated product 195.
Treatment of 195 with LiAlH4 in THF at 0 °C to reﬂux
conditions provided the desired product 196 in 78% yields
(Scheme 11).
Biological Activity. In this work, the structure−activity
relationships (SARs) focused on various substitutions and
positions of the ring-A and -B and the nature of the alkylamines
of TAs, and ring-B of PGs. Speciﬁcally, the modiﬁcations to the
ring-B of TAs and PGs were designed in order to understand
the structural requirements, as well as the necessity of the
ring-B for the potent antimalarial activity. We have synthesized
various series of novel TAs and B-ring functionalized PGs and
evaluated for antimalarial activity against the chloroquine-
sensitive (CQS) D6 and the chloroquine-resistant (CQR) Dd2
and 7G8 strains of Pf with chloroquine (CQ) as a reference
drug.66,67 In parallel, the cytotoxicity of the most potent
antimalarial PGs and TAs (IC50 < 250 nM) was tested against
hepatocellular HepG2 cancer cell line using meﬂoquine (MQ)
as a control drug (see Tables 1−6).68,69
In Vitro Antimalarial Activity of PGs (85−98). In our
previous work, synthetic PG 85 had shown an excellent
potency against Pf strains D6 (CQS) and Dd2 (CQR) with great
IC50 values (Table 1) and had the most favorable proﬁle:
92% parasite reduction at 5 mg kg−1 day−1, 100% reduction at
25 mg kg−1 day−1 in a P. yoelii murine patent infection without
any evident weight loss or clinical overt toxicity.37 To explore
the N-alkyl eﬀect on potency, initially we synthesized two
N-methylated analogues 86 and 87 of the 85 (Table 1). These
compounds 86 and 87 led to a large decrease in the antimalarial
activity (IC50 > 2250 nM) against three Pf strains D6, Dd2, and
7G8, demonstrating that both pyrrole NH groups (ring-A
and -C) of the PGs are required for potent antimalarial
activity, supporting our previous ﬁndings.38 To investigate the
importance of the methoxy group (OMe) on ring-B, two
analogues 88 and 89, in which the OMe group is replaced by
4-chlorophenyl moiety and hydrogen (complete removal of
OMe), respectively, were prepared and examined for in vitro
antimalarial activity. A dramatic loss of potency was observed
for both compounds 88 and 89, which have an IC50 of >2500 nM
against all tested Pf strains (Table 1). Interestingly, while
replacing the OMe group by ethyl unit as in 90 also led to the
reduced potency (90 IC50 = 101 nM versus 1a IC50 = 7.2 nM
against D6), the reduction was modest (14-fold). This result
demonstrated that a short aliphatic substitution at 4-position on
the ring-B could replace the OMe group and retain activity.
Together, these results highlighted the importance of the OMe
or short alkyl group on the ring-B of PGs for potent anti-
malarial activity, supporting our previous ﬁndings.38
We next investigated whether substitutions at 2 and 3 posi-
tions of the ring-B are tolerated. A series of novel B-ring func-
tionalized PGs 91−98, in which the ring-B is substituted with
Figure 4. Potential substrates (80−84) for the synthesis of PGs.
Scheme 10. Synthesis of Novel PGs (85−98) and TAs (99−187)
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either mono- and/or disubstituents at 3- and 4-positions, were
generated and examined for their in vitro antimalarial activity
(Table 1). A signiﬁcant loss of potency (IC50 > 1500 nM) was
observed for 91 and 92, containing an isopropyl and tert-butyl
groups, respectively, at 3-position on the ring-B. The adverse
eﬀect of the substitutions at 3-position on the ring-B was
further conﬁrmed by the introduction of the chloro (Cl)
substitution at 3-position of 90, as with the analogue 93, which
had an IC50 of >2500 nM against all strains (90 IC50 = 101 nM
versus 93 IC50 > 2500 nM), suggesting that the rigid bulky
substitutions or chlorine moiety (EWG) at 3-position are not
preferred (Table 1). To further investigate the impact of the
short alkyl substituents at both the 3- and 4-positions on ring-B,
a set of mixed analogues 94−98, which contain the 3-ethyl/
4-methyl groups on the ring-B, was examined. Analogues 94
and 95, which have monoalkyl groups at 5-position of the ring-C,
showed a roughly 20-fold drop in activity as compared to
undecylprodiginine (1a) (Table 1). Conversely, the analogue
96 containing a monoalkyl group at 3-position on the ring-C,
showed higher potency (3-fold) than 95 against all tested Pf
strains, while it had 9-fold lesser potency than the correspond-
ing OMe group containing analogue (IC50 = 4.6 nM against
D637). Interestingly, the analogue 97, which has 3-alkyl and
5-alkylaryl substituents on the ring-C, was equipotent to the 85,
while the analogue 98, which has 3,5-dialkylaryl substituents on
ring-C, showed ∼5-fold lower potency when compared to the
corresponding OMe group containing analogue 85 (Table 1).
Again these results are consistent and support the ﬁndings that
the 3,5-disubstitutions on ring-C are very important for potent
activity.37 In summary, these SAR analyses of the ring-B
functionalized PGs demonstrate that the short alkyl sub-
stitutions are well tolerated at 3/4-positions on the ring-B.
In Vitro Antimalarial Activity of 4-Substituted B-Ring
Functionalized TAs (99−129). Having determined the sub-
stituents impact on the antimalarial activity of the PGs (through
this and previous work37,38), we subsequently tested a hypoth-
esis that the complete replacement of the right-hand-side
alkylated pyrrole (ring-C) of PGs by alkylamines, providing the
TAs, might represent an opportunity to make potent and
selective antimalarials with the desired “druglike” properties.
Speciﬁcally, lower molecular weight (MWT) and lipophilic
properties (log P) are the two key characteristics that determine
adsorption, distribution, metabolism, excretion, and toxicity
(ADMET) liabilities, with some ADMET parameters depend-
ing more on MWT and some on log P.70 Subsequent TA
analogues 99−129 (Table 2), which have lower MWT (<400)
and cLogP (<4.2, except 114), were generated to obtain a SAR
for the alkylamines in the place of ring-C and substituents at
4-position on the ring-B.
Initially, a series of new TAs 99−112, which have various
alkyl/arylamines in the place of ring-C and the OMe group at
the 4-position on the ring-B (as in natural products), were
synthesized and evaluated for their in vitro antimalarial activity
against Pf strains, and the results are shown in Table 2. TAs
99−102 containing the n-alkylamines in the place of ring-C
exhibited good activity against all Pf strains; speciﬁcally, ana-
logues 100 and 102 showed the highest potencies (IC50 < 50 nM)
(Table 2). To probe the eﬀect of cycloalkylamines in the place
Scheme 11. Synthesis of Novel Analogues (190, 191, and 194−196)
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of ring-C/n-alkylamines on activity, we synthesized another
set of TAs 103−109 (Table 2). Of these cycloalkylated TAs,
analogues 108 and 109, which have the cyclooctylamine and
1-adamantylamine moieties, respectively, were the most potent
antimalarial candidates (108 IC50 < 7.1 nM and 109 IC50 < 3.8 nM
against all tested Pf strains; see Table 2) with good selectivity,
and these results are more comparable to the potent PG 85
(IC50 < 6.1 nM) and the natural PG 1a (IC50 < 7.5 nM). These
results clearly demonstrated that the elongation of the
cycloalkyl ring size (from cyclopropyl, 103, IC50 = 2500 nM
to 1-adamantyl, 109, IC50 < 3.1 nM) led to an increase in
activity (Table 2 and Figure 5). The greatest loss of potency
(IC50 > 2500 nM) was observed in 110, in which ring-C is
replaced by piperidine moiety, suggesting that the free NH is
required for the potent antimalarial activity. Replacement of
cyclohexyl moiety with benzylpiperidine as with 111 led to
slightly reduced potency (106 IC50 = 49 nM versus 111 IC50 =
127 nM against D6). The analogue 112, which contain a
4-chloroaniline in the place of ring-C showed the moderate
activity (Table 2). These results unequivocally demonstrate
that the ring-C of PGs can be replaced by alkylamines, provid-
ing the novel TAs with retained and/or enhanced antimalarial
and cytotoxic properties.
To investigate the importance of the OMe group on ring-B
of TAs, another set of TAs 113−119, in which the OMe
group is replaced by 4-chlorophenyl moiety, was generated and
examined for their in vitro antimalarial activity (Table 2).
In vitro analysis of the activity of these compounds 113−119
against Pf, demonstrated activity (IC50 > 250 nM) signiﬁcantly
diminished when compared to the corresponding OMe group
containing TAs (100, 102, and 105−109). This work suggested
that the bulky aromatic substitution at 4-position on the ring-B
had an adverse eﬀect on antimalarial activity. Interestingly the
replacement of the OMe group with short alkyl substituents
(methyl/ethyl) also reduced the potency of the compounds
120−122, 124, and 125 (IC50 > 250 nM) (Table 2). Con-
versely, the adamantyl analogues 123 and 126, in which the
OMe group is replaced by methyl and ethyl groups on the ring-B,
respectively, showed a substantially higher potency against
D6 strain (109 IC50 = 3.1 nM versus 123 IC50 = 1.3 nM, 126
IC50 = 2.5 nM) with great selectivity. Complete removal of the
OMe group on ring-B as with the analogues 127−129 resulted
in the total loss of activity (127, 128, IC50 > 2500 nM vs 107
IC50 = 23 nM, 108 IC50 = 4.8 nM, and 129 IC50 = 341 nM vs
109 IC50 = 3.1 nM, 123 IC50 = 1.3 nM, 126 IC50 = 2.5 nM
against D6). Together, these results again demonstrate that the
substituents at 4-position on the ring-B have an important role
in potent antimalarial activity, and the OMe group can be
replaced by short alkyl substituents (methyl/ethyl) when
1-adamantylamine exists in the place of ring-C.
In Vitro Antimalarial Activity of 3-Substituted B-Ring
Functionalized TAs (130−141). Having established the sub-
stitution pattern at 4-position on the ring-B and the terminal
alkylamines (cycloheptyl-, cyclooctyl-, and 1-adamantylamines)
as optimal, we then examined the eﬀects of substitution pattern
at 3-position, where the 4-position is vacant on the ring-B of
Table 1. In Vitro Antimalarial Activity and Cytotoxicity of PGs (85−98)
antimalarial activity
(IC50 in nM)
a
compd R1 R2 R3 R4 D6 Dd2 7G8 cytotoxicity (IC50 in nM)
a HepG2 SIb (D6) cLogPc
85 H OMe H 6.1 4.8 5.5 >250000 >40983 4.8
86 Me OMe H 2250 >2500 >2500 ntd 5.1
87 Me OMe Me >2500 >2500 >2500 nt 5.3
88 H 4-ClC6H4 H > 2500 >2500 >2500 nt 7.7
89 n-C11H23 H H H >2500 >2500 >2500 nt 5.2
90 n-C11H23 H Et H 101 66 51 18939 187 5.7
91 n-C11H23 H H i-Pr 1586 1500 >2500 nt 6.3
92 n-C11H23 H H t-Bu >2500 >2500 >2500 nt 6.7
93 n-C11H23 H Et Cl >2500 >2500 >2500 nt 5.8
94 n-C11H23 H Me Et 162 190 145 62000 383 6.1
95 n-C8H17 H Me Et 127 216 132 71000 559 4.8
96 H n-C8H17 Me Et 41 53 61 57200 1395 4.9
97 n-C7H15 4-FC6H4CH2 Me Et 6.5 7.0 5.9 82024 12619 6.7
98 4-ClC6H4CH2 4-ClC6H4CH2 Me Et 28 42 42 30600 1093 6.7
1a 7.2 7.5 7.0 nt 4.2
CQ 13 115 130 nt 3.7
MQ nt nt nt 21800 5.3
aIC50 values are the average of at least three determinations, each carried out in triplicate (±10%). In order to compare results run on diﬀerent days
and with diﬀerent batches of each stain, CQ was run as a positive control. All results obtained were “normalized” to the CQ values of 13 nM for D6,
115 nM for Dd2, and 130 nM for 7G8. bSI (selectivity index) = IC50 (cytotoxicity)/IC50 (D6).
ccLogP values were calculated using ChemBioDraw
Ultra software (version 14). dnt = not tested.
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the TAs (Table 3). To that end, we generated a series of
novel TAs 130−141, in which the 3-position on the ring-B is
occupied with alkyl groups and screened for their antimalarial
activity against Pf strains (Table 3). The greatest loss of potency
Table 2. In Vitro Antimalarial Activity and Cytotoxicity of 4-Substituted B-Ring Functionalized TAs (99−129)
aIC50 values are the average of at least three determinations, each carried out in triplicate (±10%). In order to compare results run on diﬀerent days
and with diﬀerent batches of each stain, CQ was run as a positive control. All results obtained were “normalized” to the CQ values of 13 nM for D6,
115 nM for Dd2, and 130 nM for 7G8. bSI (selectivity index) = IC50 (cytotoxicity)/IC50 (D6).
ccLogP values were calculated using ChemBioDraw
Ultra software (version 14), dnt = not tested.
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was observed when the short alkyl (methyl/ethyl) groups move
from 4-position (121−126, Table 2) to the 3-position (130−
141, Table 3). Moreover, the adamantyl analogues 132 and 135
showed a signiﬁcant decline in activity (132 IC50 =
106 nM vs 123 IC50 = 1.3 nM, and 135 IC50 = 117 nM vs
126 IC50 = 2.5 nM against D6), and the analogue 141 had an
almost total loss of activity (IC50 > 2500 nM). The one
exception is the adamantyl analogue 138, containing an
isopropyl group at 3-position on the ring-B, which showed
the better potency (IC50 < 30 nM) against all tested Pf strains
with good selectivity. These results show that generally alkyl
substitutions at 3-position versus the 4-position adversely aﬀect
the potency irrespective of the terminal alkylamines.
In Vitro Antimalarial Activity of 3,4-Disubstituted
B-Ring Functionalized TAs (142−165). Exploration of the
SARs around the ring-B of TAs indicated that the substitutions
at 4-position were greatly favored compared to the 3-position
(Tables 2 and 3). This ﬁnding is exempliﬁed by the poor
activity of the 3-substituted analogues (130−141) with the
exception of 138. We next investigated whether substitutions
at both the 3- and 4-positions are tolerated. We synthesized
a series of 3,4-disubstituted B-ring functionalized TAs 142−149,
which have 3-ethyl and 4-methyl groups on the ring-B (Table 4).
Of these 3,4-disubstituted TAs, analogues 142−144, 148, and
149 with an n-alkyl, cyclopropyl, benzylpiperidine, and morpho-
line moieties, respectively, showed diminished activity (Table 4).
Conversely, the analogues 145 and 146, which have cycloheptyl
and cyclooctyl moieties, respectively, showed the highest
potencies (Table 4) compared with those of the corresponding
3- and 4-monoalkyl substituted analogues (see Tables 2 and 3).
Signiﬁcantly, the adamantyl analogue 147 showed comparable
Figure 5. SAR of TAs (103−109) containing various cycloalkyl groups
and in vitro antimalarial activity against Pf strains D6, Dd2, and 7G8.
Table 3. In Vitro Antimalarial Activity and Cytotoxicity of 3-Substituted B-Ring Functionalized TAs (130−141)
aIC50 values are the average of at least three determinations, each carried out in triplicate (±10%). In order to compare results run on diﬀerent days
and with diﬀerent batches of each stain, CQ was run as a positive control. All results obtained were “normalized” to the CQ values of 13 nM for D6,
115 nM for Dd2, and 130 nM for 7G8. bSI (selectivity index) = IC50 (cytotoxicity)/IC50 (D6).
ccLogP values were calculated using ChemBioDraw
Ultra software (version 14). dnt = not tested.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00560
J. Med. Chem. 2015, 58, 7286−7309
7296
potency to that of the corresponding 4-alkyl/methoxy sub-
stituted analogues (147 IC50 = 5.5 nM versus 109 IC50 = 3.1 nM,
123 IC50 = 1.3 nM, 126 IC50 = 2.5 nM against D6), and this
potency is 5- to 20-fold greater than the corresponding 3-alkyl
substituted analogues (147 IC50 = 5.5 nM versus 132 IC50 =
106 nM, 135 IC50 = 117 nM, 138 IC50 = 26 nM against D6).
Interchange of the methyl and ethyl groups between 3- and
4-positions on the ring-B as in 150−152 resulted in a ∼2-fold
decrease in potency (IC50 of 150−152 vs IC50 of 145−147).
We were encouraged that the short alkyl substitutions at both
the 3- and 4-positions on the ring-B were well tolerated with
comparable and/or enhanced activities. This allowed for a
variety of diﬀerent analogues to be synthesized with repre-
sentative examples (153−165, Table 4). The analogues 153,
154, 156, 157, 159, and 160, which contain the same alkyl groups
(methyl/ethyl/-(CH2-CH2)2-) at both 3- and 4-positions on
the ring-B, and cycloheptyl/cyclooctylamines in the place of
ring-C were shown to have comparable and/or greater potency
to the dissimilar alkyl groups at both 3- and 4-positions
containing TAs. Signiﬁcantly, the adamantyl analogues 155
(IC50 < 2.4 nM), 158 (IC50 < 2.5 nM), and 161 (IC50 < 7.5 nM)
showed enhanced (2- to 8-fold) or comparable potency against
all tested Pf strains when compared to 147 (IC50 < 5.5 nM)
and 152 (IC50 < 19 nM). The biggest potency loss occurred
Table 4. In Vitro Antimalarial Activity and Cytotoxicity of 3,4-Disubstituted B-Ring Functionalized TAs (142−165)
aIC50 values are the average of at least three determinations, each carried out in triplicate (±10%). In order to compare results run on diﬀerent days
and with diﬀerent batches of each stain, CQ was run as a positive control. All results obtained were “normalized” to the CQ values of 13 nM for D6,
115 nM for Dd2, and 130 nM for 7G8. bSI (selectivity index) = IC50 (cytotoxicity)/IC50 (D6).
ccLogP values were calculated using ChemBioDraw
Ultra software (version 14). dnt = not tested.
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(IC50 > 2250 nM) when we introduced a chlorine atom at
3-position on the ring-B as in 162−165 (IC50 of 156−158 vs
163−165, Table 4), and it is consistent with the observation
that the chlorine atom (EWG) has an adverse eﬀect at 3-position
on the ring-B of PGs. Collectively, from the monoalkylated
(Tables 2 and 3) and 3,4-dialkylated TAs (Table 4) the data
clearly showed that the 3,4-disubstituted TAs containing
cycloheptyl/cyclooctyl groups have signiﬁcantly improved potency
than the corresponding monoalkylated TAs (Tables 2 and 3),
and these potencies were comparable to the corresponding
OMe group containing analogues (Table 2). Notably, all the
adamantyl analogues, which have short (alkyl/methoxy)
groups at 4-position (Table 2) and dialkyl groups at 3/4-
Table 5. In Vitro Antimalarial Activity and Cytotoxicity of A- and B-Ring Functionalized TAs (166−187)
aIC50 values are the average of at least three determinations, each carried out in triplicate (±10%). In order to compare results run on diﬀerent days
and with diﬀerent batches of each stain, CQ was run as a positive control. All results obtained were “normalized” to the CQ values of 13 nM for D6,
115 nM for Dd2, and 130 nM for 7G8. bSI (selectivity index) = IC50 (cytotoxicity)/IC50 (D6).
ccLogP values were calculated using ChemBioDraw
Ultra software (version 14). dnt = not tested.
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positions (Table 4) on ring-B, showed the greatest activity
with good selectivity.
In Vitro Antimalarial Activity of A- and B-Ring Func-
tionalized TAs (166−187). After establishing the substitu-
tions pattern at 3- and 4-positions on the ring-B of TAs, we
investigated the importance of positioning of the ring-A at
2-position on the ring-B of TAs (Table 5) by keeping the
1-adamantylamine as an active pharmacophore for all
analogues. The TAs 166−169, in which the ring-A (2-pyrrolyl
moiety) is shifted from 2- to 3-position on the ring-B and are
isomeric to 129, 123, 126, and 155 (Tables 2 and 4), respec-
tively, were synthesized and tested against Pf strains (Table 5).
It is noteworthy that the potency was signiﬁcantly declined
against all tested Pf strains after shifting the ring-A from 2- to
3-position (166−168 IC50 > 2500 nM vs 123 IC50 = 1.3 nM,
126 IC50 = 2.5 nM, 129 IC50 = 341 nM, and 169 IC50 = 1418
nM vs 155 IC50 < 2.5 nM, against D6, Tables 2, 4, and 5). The
importance of the location of nitrogen within ring-A was
analyzed by moving from the 2′-position to the 3′-position
(Figure 1 and Table 5), where compound 170 showed a
roughly 100-fold drop in activity (170 IC50 = 250 nM vs 155
IC50 < 2.5 nM, against D6, Tables 4 and 5). We also looked at
the alternatives to the ring-A at 2 position of the ring-B.
Replacement of the ring-A (2-pyrrolyl) by various 2-heteroaryl/
phenyl moieties (compounds 171−175) resulted in a decrease
in antimalarial activity (IC50 of 171−175 vs 155 and 161).
Notably, our previous SAR investigations revealed that the ring-A
(2-pyrrolyl moiety) of PGs provides optimal activity,37,38 and
the current results also suggest the importance of the ring-A of
TAs for the potent activity. Alkylation (methylation) on the
NH group of the ring-A as in 176 resulted in a large decrease in
potency (176 IC50 > 2500 nM vs 155 IC50 < 2.5 nM), sug-
gesting that the pyrrole NH (ring-A) of the TAs is important
for potent antimalarial activity. Conversely, the analogues
177−181, which contain C-alkyl moieties on the ring-A,
retained the potency against all tested Pf strains, suggesting that
the alkyl groups are well tolerated on the ring-A.
To further investigate the exact role of the ring-A of TAs on
potency, a set of mixed alkylated analogues 182−186, in which
the ring-A is completely removed from the core moiety of TAs,
were examined. Complete removal of the substitutions on the
ring-B dramatically reduced the potency of the compound 182
(IC50 > 2500 nM). Incorporation of the substitutions into the
ring-B as in 183−186 (from mono- to trialkyl) resulted in a
large increase in potency (Table 5), whereas the dimer 187 of
the 185 showed the poorest activity. It is noteworthy that the
analogues 185 and 186, which contain a monopyrrole with
trialkyl substituents and an enamine moiety, showed the com-
parable potency to that of the corresponding bipyrrole TAs.
These results demonstrated that the ring-A is not essential for
the antimalarial activity, but both the trialkylated monopyrrole
and enamine moiety are important. In summary, structure
pruning of PGs has shown that in vitro potency can be retained
and/or enhanced when moving from a tripyrrole (PGs) to
bipyrrole (TAs) and even to a monopyrrole as shown in
Figure 6.
In Vitro Antimalarial Activity of TA-like Analogues (190,
191, and 194−196), in Which the Ring-B Is Replaced by
an Alkylamide/Amine Linkage. Our detailed SAR explora-
tions around the ring-A and -B and nature of alkylamines of
TAs led to a robust understanding of the structural features that
Figure 6. Structure pruning approach of the lead PG compounds (98).
Table 6. In Vitro Antimalarial Activity of TA-like Analogues
(190, 191, and 194−196)
aIC50 values are the average of at least three determinations, each
carried out in triplicate (±10%). In order to compare results run on
diﬀerent days and with diﬀerent batches of each stain, CQ was run
as a positive control. All results obtained were “normalized” to the CQ
values of 13 nM for D6, 115 nM for Dd2, and 130 nM for 7G8.
bcLogP values were calculated using ChemBioDraw Ultra software
(version 14).
Figure 7. Summary of SAR analysis of PGs and TAs.
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are required for potent antimalarial activity. We also sought to
explore whether any linkage (total replacement of ring-B)
between two of the most active pharmacophores (i.e.,
2-pyrrolyl and 1-adamantyl moieties) is tolerated. A set of
novel TA-like analogues 190, 191, and 194−196, in which ring-
B is completely replaced by an alkylamide/amine linkage, were
generated and screened for their antimalarial activity against Pf
strains (Table 6). None of these analogues showed activity
(IC50 > 2500 nM, Table 6). These data conﬁrmed that the ring-B
between ring-A and alkylamine plays an important role in the
antimalarial activity of TAs and PGs as well.
In Vivo Eﬃcacy Studies in Mice Models. Given the
attractive antiplasmodial activity of several PGs and TAs against
CQS-D6, CQR-Dd2, and 7G8 strains of P. falciparum along with
Table 7. In Vivo Antimalarial Eﬃcacy of PGs and TAs in a Murine P. yoelii
aPrevious lead compound.37 b% suppression of parasitemia = 100 × [(parasitemia control group) − (parasitemia treated group)]/parasitemia
control group. cProvided cures (100% protection to malaria-infected mice).
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favorable toxicological properties against hepatocellular HepG2
cancer cell line and lower MWT and lipophilic properties, an
in vivo proof of concept study in a murine P. yoelii model was
undertaken with the most potent and selective analogues 98,
100, 105, 108, 109, 123, 145, 177, and 185, using side by side
comparison with our previous lead PG 8537 and CQ as
a reference drug (Table 7). In vivo eﬃcacy was determined in
a murine P. yoelii model,71,72 in which animals were randomly
placed in groups of four and administered test drugs in the
range of 5−100 mg/kg by oral gavage on 4 sequential days
following the day of inoculation. The in vivo data are expressed
as ED50 values and reﬂect the dose (estimated from dose−
response curves) for suppression of parasitemia by 50% relative
to vehicle-only controls as assessed on day 5 of each study. In
these experiments, the animals with parasitemia either on day 5
or later were euthanized and the parasitemia free animals were
kept in observation until day 28. Drug treated animals that were
parasitemia free on day 28 of the experiment are deﬁned as
“cures”, and the amount of drug that was needed to achieve a
cure is referred to as the “nonrecrudescence dose” (NRD).
Following four once-daily doses of PGs 85 and 98 at 5 mg/kg,
each reduced parasitemia by a 90% and 66% on day 5, respec-
tively, and parasitemia free animals were observed at 25 and
50−100 mg/kg; however, none of these animals were cured,
while the CQ was also not curative in this model even at doses
as high as 64 mg kg−1 day−1 (Table 7). The TA analogues 100,
105, and 108 each reduced parasitemia >90% after 5, 25, and
50 mg/kg × 4 days dosing, and at the higher dose (100 mg/kg ×
4 days) these reduced parasitemia 100% on day 5. Intriguingly,
the TA 109 with good in vitro potency showed much less
eﬃcacy with an ED50 value of 84 mg kg
−1 day−1, which may
relate to low aqueous solubility and/or poor oral bioavailability
(Table 7). Interestingly the analogue 123, in which the methyl
group of ring-B is replaced the OMe group of 109, showed
improved eﬃcacy at all doses; speciﬁcally 100% reduction was
observed at 50 mg/kg × 4 days on day 5. Of these TAs, the
analogue 145 with 3-ethyl/4-methyl substitution pattern on the
ring-B and the cycloheptylamine in the place of ring-C provided
an excellent in vivo eﬃcacy against P. yoelii in mice with an ED50
value of < 2.5 mg kg−1 day−1, and it cleared all parasitemia on day
5 after dosing 5 mg/kg to 100 mg/kg × 4 days. Indeed, the
compound 145 provided parasite-free cures on day 28 (100%
protection to malaria-infected mice) at 25 and 50 mg kg−1 day−1,
without evident weight loss and toxicity. In separate experiments,
a single oral dose (80 mg/kg) of KAR425 (145) was also used.
The preliminary experiments demonstrated that the KAR425 is
also curative in this model and two of four mice were cured with
no obvious signs of toxicity or behavior change; higher dose
studies are underway in our laboratories. The analogues 177
and 185 showed 100% parasitemia reduction on day 5 after
25−100 mg/kg and 100 mg/kg dosing, respectively; however
these were not curative in this model.
■ CONCLUSIONS
We report here the synthesis and antimalarial activity of the
novel class of potent tambjamines (TAs) and B-ring function-
alized prodiginines (PGs). The compounds were synthesized
via simple and inexpensive chemical procedures using easily
available building blocks to respond to the demand for low-cost
novel antimalarial agents. When compared to tripyrrole PGs,37,38
these bipyrrole TAs exhibited marked improvements with regard
to the color properties, in vitro potency, selectivity, and in vivo
eﬃcacy. Several key ﬁndings emerged from these studies: (i)
the alkylated pyrrole (ring-C) can be replaced by an alkyl/
cycloalkylamine, providing for TAs with retained and/or
enhanced antimalarial activity; (ii) the OMe group at the
4-position on the ring-B, between ring-A and ring-C/alkylamine
of PGs/TAs, can be replaced with short alkyl substitutions at
either 4-position or 3- and 4-positions without impacting
in vitro potency; (iii) the 2-pyrrolyl moiety (ring-A) must be linked
at 2-position on the ring-B for potency, and it can be substituted
with alkyl groups (see Figure 7). In addition, these analogues are
equally eﬀective against P. falciparum pansensitive D6 and
MDR Dd2 and 7G8 strains. Some of these analogues have
shown very promising in vivo eﬃcacy in mice; speciﬁcally, the
KAR425 (145) TA oﬀered greater eﬃcacy than previously
observed for any tripyrrole PG, providing 100% protection to
malaria-infected mice until day 28 at doses of 25 and 50 mg/kg ×
4 days, and was also curative in this model in a single oral dose
(80 mg/kg). In our overall study, the KAR425 stands out as an
excellent lead compound, with low molecular weight (<300),
good lipophilic proﬁle (cLogP < 2.7), oral eﬃcacy, and no
obvious signs of toxicity or behavior change. Detailed lead
optimization, pharmacology, safety, and modes of action studies
of the KAR425 will be studied in our laboratories in due course
to produce the antimalarial candidates for full preclinical studies.
■ EXPERIMENTAL SECTION
General. NMR spectra were recorded on Bruker AMX-400 and
AMX-600, spectrometers at 400, 600 MHz (1H) and 100, 150 MHz
(13C). Experiments were recorded in CDCl3, CD3OD, acetone-d6, and
DMSO-d6 at 25 °C. Chemical shifts are given in parts per million
(ppm) downﬁeld from internal standard Me4Si (TMS). HRMS (ESI)
were recorded on a high-resolution (30000) thermo LTQ-Orbitrap
Discovery hybrid mass spectrometer (San Jose, CA). Unless otherwise
stated, all reagents and solvents were purchased from commercial
suppliers and used without further puriﬁcation. Reactions that required
the use of anhydrous, inert atmosphere techniques were carried out
under an atmosphere of argon/nitrogen. Chromatography was executed
on CombiFlash Rf 200 instrument, using silica gel (230−400 mesh)
and/or neutral alumina as the stationary phase and mixtures of ethyl
acetate and hexane as eluents. Analytical HPLC analyses were per-
formed on a Supelco Discovery HS C18 column (4.6 mm × 250 mm)
with a linear elution gradient ranging from CH3OH/CH3CN/H2O
(40%/10%/50%) to CH3OH (100%) in 0.15% triﬂuoroacetic acid at a
ﬂow rate of 1 mL/min. A purity of ≥95% has been established for all
tested compounds.
Synthesis of 4-Hydroxy-2-oxo-2,5-dihydropyrrole-1-car-
boxylic Acid tert-Butyl Ester (45). To a stirred solution of
N-(tert-butoxycarbonyl)glycine (44; 5.0 g, 28.57 mmol) in 90 mL
of anhydrous CH2Cl2 (DCM) were added Meldrum’s acid (4.93 g,
34.28 mmol) and 4-dimethylaminopyridine (DMAP; 8.71 g, 71.42 mmol)
under an argon atmosphere at 0 °C. A solution of isopropyl chloro-
formate (42.85 mL, 42.85 mmol, 1 N in toluene) was added dropwise,
and the reaction mixture was stirred for 4 h at 0 °C. The reaction
mixture was diluted with DCM (100 mL), washed with 15% KHSO4
(2 × 70 mL), and organic layer was dried over Na2SO4, and the
solvent was evaporated under reduced pressure to give the acylated
Meldrum’s acid. This material was then reﬂuxed in ethyl acetate
(600 mL) for 1 h, and the solvent was evaporated under reduced
pressure, and the product was recrystallized from ethyl acetate to
give the desired product 45 (3.46 g, 61%) as a white solid. 1H NMR
(DMSO-d6, 400 MHz) δ 12.13 (br s, 1H), 4.88 (s, 1H), 4.14 (s, 2H),
1.44 (s, 9H); HRMS (ESI) calcd for C9H13NaNO4 (M + Na)
+
222.0737, found 222.0740.
Synthessis of 2-Oxo-4-(toluene-4-sulfonyloxy)-2,5-dihydro-
pyrrole-1-carboxylic Acid tert-Butyl Ester (46). To a stirred
solution of 45 (3.4 g, 17.08 mmol) in anhydrous CH2Cl2 (150 mL)
were added p-toluenesulfonyl chloride (3.24 g, 17.08 mmol) and
DIPEA (4.4 g, 34.17 mmol). The resulting reaction mixture was stirred
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for 6 h at 25 °C. Then the reaction mixture was washed with 5% HCl
(2 × 25 mL), brine and dried over anhydrous Na2SO4. The organic
solvent was removed under reduced pressure and the product was
chromatographed on silica gel, with ethyl acetate/hexanes as eluent, to
aﬀord 46 (5.37 g, 89%) as a white solid. 1H NMR (CDCl3, 400 MHz)
δ 7.86 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 5.75 (s, 1H), 4.22
(d, J = 1.2 Hz, 2H), 2.50 (s, 3H), 1.52 (s, 9H); HRMS (ESI) calcd for
C16H19NaNO6S (M + Na)
+ 376.0825, found 376.0830.
Synthesis of 4-(4-Chlorophenyl)-2-oxo-2,5-dihydropyrrole-
1-carboxylic Acid tert-Butyl Ester (47). To a degassed stirred
solution of 46 (4.0 g, 11.33 mmol) and 4-chlorophenylboronic acid
(2.65 g, 17.0 mmol) in 100 mL of THF at room temperature were
added Pd(dppf)Cl2 (410 mg, 0.56 mmol) and a solution of cesium
carbonate (11.05 g, 34.0 mmol) in water (15 mL). The reaction
mixture was stirred at 25 °C for 1 h and then heated to reﬂux for 16 h.
The reaction mixture was ﬁltered through Celite and washed with
ethyl acetate (400 mL). The organic layer was washed with saturated
sodium bicarbonate (2 × 75 mL) and brine and dried over anhydrous
Na2SO4. Then the organic solution was concentrated under reduced
pressure and the product was chromatographed on silica gel, with ethyl
acetate/hexanes as eluent, to aﬀord the pure product 47 (1.82 g, 55%)
as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.50 (d, J = 8.7 Hz,
2H), 7.42 (d, J = 8.7 Hz, 2H), 6.42 (t, J = 1.5 Hz, 1H), 4.68 (d, J =
1.5 Hz, 2H), 1.61 (s, 9H); HRMS (ESI) calcd for C15H16NaClNO3
(M + Na)+ 316.0711, found 316.0713.
Synthesis of 4-(4-Chlorophenyl)-1,5-dihydropyrrol-2-one
(48). To a stirred solution of 47 (1.8 g, 6.14 mmol) in anhydrous
CH2Cl2 (25 mL) was added dropwise TFA (2.8 g, 24.57 mmol). The
reaction mixture was stirred for an additional hour at 25 °C. The
solvent was evaporated under reduced pressure, and the crude material
was then dissolved in ethyl acetate (200 mL). The organic layer was
washed with 5% NaHCO3 and brine and dried over anhydrous
Na2SO4. The organic solvent was evaporated under reduced pressure
and the solid material was washed with CH2Cl2 to aﬀord the pure
product 48 (1.14 g, 94%) as a white solid. 1H NMR (DMSO-d6,
400 MHz) δ 8.15 (br s, 1H), 7.61 (d, J = 8.6 Hz, 2H), 7.44 (d, J = 8.6
Hz, 2H), 6.50 (t, J = 1.5 Hz, 1H), 4.30 (s, 2H); HRMS (ESI) calcd for
C10H9ClNO (M + H)
+ 194.0367, found 194.0372.
Synthesis of 5-Bromo-3-(4-chlorophenyl)pyrrole-2-carbox-
aldehyde (49). To a stirred solution of diethylformamide (DEF;
1.57 g, 15.54 mmol) in anhydrous chloroform (10 mL) at 0 °C was
added dropwise a solution of phosphorus oxybromide (POBr3; 3.62 g,
12.95 mmol) in chloroform (10 mL). The resulting thick suspension
was stirred at 0 °C for 30 min to obtain the Vilsmeier complex
as a solid. After the sample was dried in vacuo for 20 min, chloroform
(50 mL) was added to the solid and the reaction mixture was cooled to
0 °C. The compound 48 (1.0 g, 5.18 mmol) was added portionwise,
and the reaction mixture was warmed to room temperature and then
heated at 70 °C for 16 h. The reaction mixture was poured onto ice−
water (75 mL), and the pH of the aqueous solution was adjusted to
pH 9−10 by treatment with 5 N NaOH. Dichloromethane (100 mL)
was added to the resulting precipitate, and the mixture was ﬁltered
through Celite. The two layers were separated, and the aqueous layer
was extracted with CH2Cl2 (3 × 100 mL). The organic layers were
combined, washed with brine, and dried over anhydrous Na2SO4. The
solvent was removed under reduced pressure and the product was
passed through a silica gel, with ethyl acetate/hexanes as eluent, to
aﬀord the pure 49 (806 mg, 55%) as a white solid. 1H NMR (CDCl3,
400 MHz) δ 10.05 (br s, 1H), 9.49 (s, 1H), 7.49−7.40 (m, 4H), 6.42
(d, J = 2.6 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 178.2, 137.1,
134.5, 131.5, 130.9, 130.3, 129.9, 129.1, 128.9, 113.6, 113.1; HRMS
(ESI) calcd for C11H8BrClNO (M + H)
+ 283.9472, found 283.9484.
Representative Procedure for the Synthesis of 4-(4-Chloro-
phenyl)-[2,2′]bipyrrolyl-5-carboxaldehyde (9). To a degassed
stirred solution of 49 (1.0 g, 3.53 mmol) and N-Boc-2-pyrroleboronic
acid (1.11 g, 5.30 mmol) in 10% water/dioxane (50 mL) were added
Pd(PPh3)4 (204 mg, 0.17 mmol) and Na2CO3 (749 mg, 7.06 mmol).
The reaction mixture was stirred for 3 h at 100 °C and poured onto
water (100 mL). The pH of the solution was lowered to pH 7 with
2 N HCl and extracted with ethyl acetate (3 × 75 mL). The combined
organic layers were washed with water and brine and dried over
anhydrous Na2SO4. The solvent was evaporated under reduced pres-
sure and the residue was dissolved in methanol (25 mL) and
evaporated the solvent to remove the volatile B(OMe)3. This was then
dissolved in THF (10 mL), and LiOH (850 mg, 35.33 mmol) in
methanol (10 mL) was added dropwise under an argon atmosphere at
room temperature. The resulting reaction mixture was stirred at room
temperature for 30 min. On completion of the reaction, the solvent
was removed under reduced pressure. The resulting solid was picked
up with ethyl acetate (200 mL), washed with water and brine, and
dried over anhydrous Na2SO4. The organic solvent was removed
under reduced pressure and the product was chromatographed on
silica gel, with ethyl acetate/hexanes as eluent, to aﬀord the pure 9
(562 mg, 59%). 1H NMR (DMSO-d6, 400 MHz) δ 12.09 (br s, 1H),
11.31 (br s, 1H), 9.46 (s, 1H), 7.58 (d, J = 8.7 Hz, 2H), 7.52 (d, J = 8.7
Hz, 2H), 6.93 (m, 1H), 6.81 (m, 1H), 6.72 (d, J = 2.5 Hz, 1H), 6.14
(m, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 177.1, 135.6, 133.6,
132.6, 132.3, 130.5 (2C), 128.7 (2C), 127.5, 123.0, 120.2, 109.3, 108.1,
106.4; HRMS (ESI) calcd for C15H12ClN2O (M + H)
+ 271.0633,
found 271.0639.
Synthesis of 5-Chloropyrrole-2-carboxaldehyde (51). To a
stirred solution of pyrrole (50; 5.0 g, 74.62 mmol) in 200 mL of dry
THF was added N-chlorosuccinimide (NCS; 9.92 g, 74.62 mmol)
under an argon atmosphere at −78 °C. The reaction mixture was
stirred for an additional 4 h at the same temperature and placed at −20 °C
for overnight. To the reaction mixture was added dropwise Vilsmeier
reagent (149.25 mmol, in situ generation from POCl3/DMF, 0 °C,
1 h) in 100 mL of DCM at −20 °C. The reaction mixture was stirred
for 10 h while it was allowed to warm to room temperature. The
solvent was removed under reduced pressure, and 100 mL of water
was added. To the stirred mixture, sodium hydroxide (2 N, 100 mL)
was added slowly, and the reaction mixture was allowed to stir for 1 h
at room temperature. Ethyl acetate (300 mL) was added to the
resulting precipitate, the two layers were separated, and the aqueous
layer was further extracted with ethyl acetate (2 × 100 mL). The
organic layers were combined, washed with brine, and dried over
anhydrous Na2SO4. The solvent was removed by rotary evaporation
and the product was chromatographed on silica gel, with ethyl acetate/
hexanes as eluent, to aﬀord the desired product 51 (3.46 g, 36%) as a
white solid. 1H NMR (CDCl3, 400 MHz) δ 12.28 (br s, 1H), 9.31 (s,
1H), 6.85 (dd, J = 2.3, 4.0 Hz, 1H), 6.14 (dd, J = 2.3, 4.0 Hz, 1H); 13C
NMR (CDCl3, 100 MHz) δ 178.2, 131.9, 126.0, 122.4, 110.0; HRMS
(ESI) calcd for C5H5ClNO (M + H)
+ 130.0054, found 130.0055.
Synthesis of [2,2′-Bipyrrole]-5-carboxaldehyde (19). Com-
pound 19 (558 mg, 45%) was synthesized by the same procedure as
described for 9. 1H NMR (CDCl3, 400 MHz) δ 11.98 (br s, 1H),
11.24 (br s, 1H), 9.35 (s, 1H), 7.00 (dd, J = 2.3, 3.9 Hz, 1H), 6.89 (m,
1H), 6.73 (m, 1H), 6.54 (dd, J = 2.3, 3.9 Hz, 1H), 6.12 (m, 1H);
HRMS (ESI) calcd for C9H9N2O (M + H)
+ 161.0709, found 161.0713.
Synthesis of Ethyl 4,5,6,7-Tetrahydroisoindole-1-carboxy-
late (53). To a stirred solution of 52 (5.0 g, 39.37 mmol) and ethyl
isocyanoacetate (5.33 g, 47.24 mmol) in 1:1 mixture of THF and
ethanol (100 mL) was added portionwise anhydrous potassium
carbonate (10.86 g, 78.74 mmol). The reaction mixture was then
stirred at room temperature for 3 days. The mixture was poured into
water (100 mL), acidiﬁed to pH 5 with 2 N HCl, and extracted with
diethyl ether (3 × 100 mL). The combined organic layers were washed
with brine and dried over anhydrous Na2SO4. The solvent was evap-
orated under reduced pressure and the product was chromatographed
on silica gel, with ethyl acetate/hexanes as eluent, to aﬀord the pure
product 53 (4.93 g, 65%) as a white solid. 1H NMR (CDCl3, 400 MHz)
δ 9.28 (br s, 1H), 6.67 (d, J = 2.9 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H),
2.85 (t, J = 5.8 Hz, 2H), 2.57 (t, J = 6.0 Hz, 2H), 1.77 (m, 4H), 1.38 (t,
J = 7.1 Hz, 3H); HRMS (ESI) calcd for C11H16NO2 (M + H)
+
194.1176, found 194.1184.
Synthesis of 4,5,6,7-Tetrahydroisoindole (54). Sodium hydroxide
(1.47 g, 36.71 mmol) was added to a solution of 53 (3.8 g, 18.35 mmol) in
anhydrous ethylene glycol (20 mL) under an argon atmosphere at room
temperature, and the reaction mixture was heated to reﬂux and stirred
at reﬂuxing temperature for an hour. After cooling to room temperature,
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the reaction mixture was taken up in n-hexane, washed with water and
dried over anhydrous Na2SO4. Evaporation of the solvent under reduced
pressure aﬀorded the 54 (2.0 g, 90%) as a white solid that was directly
used in the next step without further puriﬁcation. 1H NMR (CDCl3,
400 MHz) δ 7.92 (br s, 1H), 6.53 (d, J = 2.6 Hz, 2H), 2.67 (m, 4H),
1.80 (m, 4H); HRMS (ESI) calcd for C8H12N (M + H)
+ 122.0964,
found 122.0969.
Representative Procedure for the Synthesis of 4,5,6,7-
Tetrahydroisoindole-1-carboxaldehyde (55) by Standard Vils-
meier Conditions. Phosphorus oxychloride (POCl3; 5.05 g, 33.05
mmol) was added dropwise to dimethylformamide (DMF; 2.41 g,
33.05 mmol) at 0 °C. The resulting solution was stirred at 0 °C until
the formation of the Vilsmeier complex as a solid. After the solid was
dried in vacuo for 20 min, dichloromethane (50 mL) was added to the
solid and the reaction mixture was cooled to 0 °C. A solution of 54
(2.0 g, 16.52 mmol) in DCM (50 mL) was added dropwise, and the
reaction mixture was warmed to room temperature and then stirred
for 10 h. After removal of all solvent under vacuo, the residue was
mixed with water (100 mL). To the stirred mixture, sodium hydroxide
(5.28 g, 132.23 mmol) was added slowly, and the reaction mixture was
allowed to stir for 1 h at room temperature. Ethyl acetate (200 mL)
was added to the resulting precipitate, the two layers were separated,
and the aqueous layer was further extracted with ethyl acetate
(2 × 50 mL). The organic layers were combined, washed with brine,
and dried over anhydrous Na2SO4. The solvent was removed by rotary
evaporation and the product was chromatographed on silica gel, with
ethyl acetate/hexanes as eluent, to aﬀord the desired product 55
(1.84 g, 75%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 10.23
(br s, 1H), 9.51 (s, 1H), 6.87 (d, J = 2.8 Hz, 1H), 2.86 (t, J = 5.9 Hz,
2H), 2.55 (t, J = 6.0 Hz, 2H), 1.80 (m, 4H); HRMS (ESI) calcd for
C9H12NO (M + H)
+ 150.0913, found 150.0920.
Representative Procedure for the Synthesis of 3-Bromo-
4,5,6,7-tetrahydroisoindole-1-carboxaldehyde (56). To a stirred
solution of 55 (2.0 g, 13.42 mmol) in THF (100 mL) was added
portionwise DBDMH (1.90 g, 6.71 mmol) in a period of 10 min
at −78 °C. Then the reaction mixture was stirred for 5 h while it was
allowed to warm to room temperature. The reaction was quenched
with 5% aqueous KHSO4 solution and extracted with ethyl acetate
(3 × 75 mL). The combined organic layers were washed with brine
and dried over anhydrous Na2SO4. The solvent was evaporated under
reduced pressure and the product was chromatographed on silica gel,
with ethyl acetate/hexanes as eluent, to aﬀord the pure product 56
(2.48 g, 82%). 1H NMR (CDCl3, 400 MHz) δ 10.60 (br s, 1H), 9.41
(s, 1H), 2.83 (m, 2H), 2.42 (m, 2H), 1.77 (m, 4H); 13C NMR
(CDCl3, 100 MHz) δ 175.7, 134.7, 128.9, 122.7, 110.5, 22.8, 22.6,
21.3, 21.0; HRMS (ESI) calcd for C9H11BrNO (M + H)
+ 228.0019,
found 228.0031.
Synthesis of 3-(Pyrrol-2-yl)-4,5,6,7-tetrahydroisoindole-1-
carboxaldehyde (20). Compound 20 (682 mg, 72%) was syn-
thesized by the same procedure as described for 9. 1H NMR (DMSO-d6
+ CDCl3, 400 MHz) δ 10.64 (br s, 1H), 10.35 (br s, 1H), 8.77 (s, 1H),
6.21 (s, 1H), 5.81 (s, 1H), 5.56 (s, 1H), 2.19 (s, 2H), 1.98 (s, 2H), 1.16
(m, 4H); 13C NMR (DMSO-d6 + CDCl3, 100 MHz) δ 173.0, 133.1,
128.8, 125.6, 122.5, 117.9, 116.7, 108.2, 107.5, 21.9, 21.5, 21.1, 19.6;
HRMS (ESI) calcd for C13H15N2O (M + H)
+ 215.1179, found 215.1188.
Synthesis of Compounds 59−62. Compounds 59 (1.36 g, 75%),
60 (1.27 g, 78%), 61 (1.35 g, 79%), and 62 (1.35 g, 83%) were syn-
thesized by the same procedure as described for 56.
4-Bromopyrrole-2-carboxaldehyde (59). 1H NMR (CDCl3, 400
MHz) δ 10.16 (br s, 1H), 9.49 (d, J = 1.0 Hz, 1H), 7.15 (m, 1H), 7.00
(m, 1H); HRMS (ESI) calcd for C5H5BrNO (M + H)
+ 173.9549,
found 173.9555.
4-Bromo-3,5-dimethylpyrrole-2-carboxaldehyde (60). 1H NMR
(CDCl3, 400 MHz) δ 10.82 (br s, 1H), 9.45 (s, 1H), 2.36 (s, 3H),
2.28 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 176.2, 137.0, 133.0,
127.7, 101.5, 12.2, 10.0; HRMS (ESI) calcd for C7H9BrNO (M + H)
+
201.9862, found 201.9871.
4-Bromo-3-methylpyrrole-2-carboxaldehyde (61). 1H NMR
(acetone-d6, 400 MHz) δ 11.17 (br s, 1H), 9.69 (d, J = 0.7 Hz, 1H),
7.25 (d, J = 3.2 Hz, 1H), 2.32 (s, 3H); HRMS (ESI) calcd for
C6H7BrNO (M + H)
+ 187.9705, found 187.9711.
4-Bromo-3-ethylpyrrole-2-carboxaldehyde (62). 1H NMR (CDCl3,
400 MHz) δ 10.08 (br s, 1H), 9.34 (s, 1H), 7.20 (d, J = 2.6 Hz, 1H),
2.47 (q, J = 7.6 Hz, 2H), 1.25 (t, J = 7.6 Hz, 3H); HRMS (ESI) calcd for
C7H9BrNO (M + H)
+ 201.9862, found 201.9869.
Synthesis of 22−25. Compounds 22 (647 mg, 70%), 23 (673 mg,
72%), 24 (623 mg, 67%), and 25 (608 mg, 65%) were synthesized
by the same procedure as described for 9, with modiﬁcation of the
reaction conditions for deprotection of N-Boc group. The crude
material was dissolved in THF (10 mL), and LiOH (10 equiv) in
methanol (10 mL) was added dropwise under an argon atmosphere.
The resulting mixture was stirred at 60 °C for 2 h.
[2,3′-Bipyrrole]-5′-carboxaldehyde (22). 1H NMR (CD3OD, 400
MHz) δ 9.43 (d, J = 1.0 Hz, 1H), 7.37 (dd, J = 1.6, 2.5 Hz, 1H), 7.15
(d, J = 1.6 Hz, 1H), 6.70 (dd, J = 1.5, 2.7 Hz, 1H), 6.23 (dd, J =
1.5, 3.4 Hz, 1H), 6.10 (dd, J = 2.7, 3.4 Hz, 1H); 13C NMR (CD3OD,
100 MHz) δ 180.7, 134.4, 127.7, 123.8, 122.6, 118.1, 117.2, 109.4,
104.7; HRMS (ESI) calcd for C9H9N2O (M + H)
+ 161.0709, found
161.0713. Note: Two NH protons are not appearing under these
conditions.
2′,4′-Dimethyl-[2,3′-bipyrrole]-5′-carboxaldehyde (23). 1H NMR
(DMSO-d6, 400 MHz) δ 11.68 (br s, 1H), 10.59 (br s, 1H), 9.51 (s,
1H), 6,76 (br s, 1H), 6.08 (br s, 1H), 5.94 (br s, 1H), 2.28 (s, 3H),
2.24 (s, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 176.4, 135.2, 129.8,
127.7, 124.2, 117.3, 117.1, 107.9, 107.0, 12.1, 9.5; HRMS (ESI) calcd
for C11H13N2O (M + H)
+ 189.1022, found 189.1026.
4′-Methyl-[2,3′-bipyrrole]-5′-carboxaldehyde (24). 1H NMR
(DMSO-d6, 600 MHz) δ 11.78 (br s, 1H), 10.78 (br s, 1H), 9.64
(s, 1H), 7.33 (d, J = 3.0 Hz, 1H), 6.71 (dd, J = 1.8, 2.4 Hz, 1H), 6.10
(dd, J = 1.8, 3.0 Hz, 1H), 6.07 (dd, J = 2.4, 3.0 Hz, 1H), 2.41 (s, 3H);
13C NMR (DMSO-d6 + CDCl3, 100 MHz) δ 176.2, 128.7, 125.8,
124.5, 122.1, 118.1, 115.6, 107.1, 104.0, 8.9; HRMS (ESI) calcd for
C10H11N2O (M + H)
+ 175.0866, found 175.0871.
4′-Ethyl-[2,3′-bipyrrole]-5′-carboxaldehyde (25). 1H NMR
(DMSO-d6, 600 MHz) δ 9.69 (s, 1H), 7.40 (d, J = 2.7 Hz, 1H),
6.70 (dd, J = 1.7, 2.7 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 6.16 (dd, J =
2.7, 3.2 Hz, 1H), 2.70 (q, J = 7.3 Hz, 2H), 1.12 (t, J = 7.3 Hz, 3H);
HRMS (ESI) calcd for C11H13N2O (M + H)
+ 189.1022, found
189.1027. Note: Two NH protons are not appearing under these
conditions.
Synthesis of 26−31. Compounds 26 (276 mg, 55%), 27 (266 mg,
57%), 28 (296 mg, 63%), 29 (346 mg, 68%), 30 (346 mg, 67%),
and 31 (385 mg, 65%) were synthesized by the same procedure as
described for 9 with modiﬁcation of the reaction conditions for the
deprotection of N-triisopropylsilyl group. The crude material was
dissolved in THF (10 mL), and TBAF (2 equiv) was added dropwise
under an argon atmosphere. The resulting mixture was stirred at room
temperature for 15 min.
1′,3,4-Trimethyl-[2,2′-bipyrrole]-5-carboxaldehyde (26). 1H NMR
(CDCl3, 400 MHz) δ 9.62 (s, 1H), 8.84 (br s, 1H), 6.77 (dd, J = 1.8,
2.4 Hz, 1H), 6.28 (dd, J = 1.8, 3.7 Hz, 1H), 6.23 (dd, J = 2.4, 3.7 Hz,
1H), 3.61 (s, 3H), 2.33 (s, 3H), 2.02 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 176.8, 131.8, 129.6, 129.0, 124.3, 124.2, 120.4, 111.3, 108.4,
34.8, 9.6, 9.0; HRMS (ESI) calcd for C12H14NaN2O (M + Na)
+
225.0998, found 225.1006.
3,4-Dimethyl-[2,3′-bipyrrole]-5-carboxaldehyde (27). 1H NMR
(CDCl3, 400 MHz) δ 9.52 (s, 1H), 9.10 (br s, 1H), 8.64 (br s, 1H),
7.12 (m, 1H), 6.89 (m, 1H), 6.48 (m, 1H), 2.31 (s, 3H), 2.15 (s, 3H);
13C NMR (CDCl3, 100 MHz) δ 175.4, 134.3, 133.3, 127.9, 119.1,
117.1, 116.6, 115.5, 106.9, 9.8, 8.9; HRMS (ESI) calcd for C11H12NaN2O
(M + Na)+ 189.1022, found 189.1028.
5-(Furan-2-yl)-3,4-dimethylpyrrole-2-carboxaldehyde (28). 1H
NMR (CDCl3, 400 MHz) δ 9.63 (s, 1H), 9.52 (br s, 1H), 7.48 (dd,
J = 1.6, 2.8 Hz, 1H), 6.64 (dd, J = 1.6, 3.6 Hz, 1H), 6.52 (dd, J = 2.8,
3.6 Hz, 1H), 2.30 (s, 3H), 2.17 (s, 3H); 13C NMR (CDCl3, 100 MHz)
δ 176.8, 146.5, 142.1, 132.1, 128.6, 128.0, 117.9, 111.9, 107.8, 9.6, 8.6;
HRMS (ESI) calcd for C11H11NaN2O (M + Na)
+ 212.0682, found
212.0689.
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3,4-Dimethyl-5-(thiophen-2-yl)pyrrole-2-carboxaldehyde (29).
1H NMR (CDCl3, 400 MHz) δ 9.63 (s, 1H), 9.53 (br s, 1H), 7.37
(dd, J = 1.6, 2.7 Hz, 1H), 7.34 (dd, J = 1.6, 3.5 Hz, 1H), 7.13 (dd, J =
2.7, 3.5 Hz, 1H), 2.33 (s, 3H), 2.21 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 176.8, 133.6, 132.6, 131.4, 128.9, 127.8, 125.7, 124.2, 118.9,
9.9, 8.9; HRMS (ESI) calcd for C11H11NaNOS (M + Na)
+ 228.0454,
found 228.0459.
3,4-Dimethyl-5-phenylpyrrole-2-carboxaldehyde (30). 1H NMR
(CDCl3, 400 MHz) δ 9.64 (s, 1H), 9.49 (br s, 1H), 7.52 (m, 2H),
7.46 (m, 2H), 7.39 (m, 1H), 2.34 (s, 3H), 2.17 (s, 3H); 13C NMR
(CDCl3, 100 MHz) δ 176.9, 137.0, 132.6, 131.7, 129,0, 128.9 (2C),
128.2, 127.8 (2C), 118.6, 9.8, 9.0; HRMS (ESI) calcd for C13H13NaNO
(M + Na)+ 222.0889, found 222.0897.
5-(Indol-2-yl)-3,4-dimethylpyrrole-2-carboxaldehyde (31). 1H
NMR (DMSO-d6, 400 MHz) δ 11.43 (br s, 2H), 9.62 (s, 1H), 7.44
(m, 2H), 7.09 (m, 2H), 6.82 (s, 1H), 2.29 (s, 3H), 2.21 (s, 3H); 13C
NMR (CDCl3 + DMSO-d6, 100 MHz) δ 177.1, 136.1, 130.9, 129.6,
129.2, 128.8, 128.3, 122.1, 120.2, 119.6, 118.4, 111.2, 101.5, 10.0, 8.5;
HRMS (ESI) calcd for C15H15N2O (M + H)
+ 239.1179, found
239.1188.
Representative Procedure for the Synthesis of 2-Ethyl-
pyrrole (67a). To a stirred suspension of LiAlH4 (3.49 g, 91.74 mmol)
in dry THF (50 mL) was added dropwise 66a (5.0 g, 45.87 mmol) in
THF (50 mL) at 0 °C. Then the resulting solution was heated to reﬂux
overnight. The reaction was quenched with saturated solution of sodium
sulfate. The insoluble solid was ﬁltered oﬀ and washed with DCM
(100 mL). Then the combined organic solution was concentrated
under reduced pressure and the product was chromatographed on
silica gel, with ethyl acetate/hexanes as eluent, to aﬀord the desired
product 67a (4.0 g, 92%).
2-Isobutylpyrrole (67b). Yield: 4.26 g, 95%. HRMS (ESI) calcd for
C8H14N (M + H)
+ 124.1121, found 124.1126.
Representative Procedure for the Synthesis of tert-Butyl 2-
Ethyl-pyrrole-1-carboxylate (68a). 4-Dimethylaminopyridine
(DMAP; 257 mg, 2.10 mmol) was added to a stirred solution of
67a (2.0 g, 21.05 mmol) and di-tert-butyl dicarbonate (Boc2O; 6.23 g,
27.36 mmol) in acetonitrile (50 mL), and the reaction was left to stir
for 1 h at room temperature. Dichloromethane (150 mL) was added,
and the solution was washed with water and brine and dried over
anhydrous Na2SO4. The solvent was removed by rotary evaporation
and the product was chromatographed on silica gel, with ethyl acetate/
hexanes as eluent, to aﬀord the pure 68a (3.90 g, 95%). HRMS (ESI)
calcd for C11H18NO2 (M + H)
+ 196.1332, found 196.1335.
tert-Butyl 2-Isobutylpyrrole-1-carboxylate (68b). Yield: 3.40 g,
94%. 1H NMR (CDCl3, 400 MHz) δ 7.21 (dd, J = 1.6, 2.4 Hz, 1H),
6.09 (dd, J = 1.6, 3.6 Hz, 1H), 5.95 (dd, J = 2.4, 3.6 Hz, 1H), 2.73 (d,
J = 7.0 Hz, 2H), 1.93 (m, 1H), 1.61 (s, 9H), 0.94 (d, J = 6.3 Hz, 6H);
13C NMR (CDCl3, 100 MHz) δ 149.6, 135.1, 120.9, 112.3, 109.7, 83.1,
37.8, 28.0 (3C), 27.7, 22.5 (2C): HRMS (ESI) calcd for C13H22NO2
(M + H)+ 224.1645, found 224.1649.
tert-Butyl 2,4-Dimethylpyrrole-1-carboxylate (68c). Yield: 3.77 g,
92%. 1H NMR (CDCl3, 400 MHz) δ 6.94 (s, 1H), 5.80 (s, 1H), 2.41
(s, 3H), 2.02 (s, 3H), 1.60 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ
149.6, 131.6, 120.4, 117.5, 114.2, 82.8, 28.1 (3C), 15.4, 11.7; HRMS
(ESI) calcd for C11H18NO2 (M + H)
+ 196.1332, found 196.1339.
tert-Butyl 3-Ethyl-2,4-dimethylpyrrole-1-carboxylate (68d). Yield:
3.26 g, 90%. 1H NMR (CDCl3, 400 MHz) δ 6.96 (s, 1H), 2.38 (q, J =
7.6 Hz, 2H), 2.37 (s, 3H), 2.01 (s, 3H), 1.61 (s, 9H), 1.07 (t, J = 7.6
Hz, 3H); HRMS (ESI) calcd for C13H22NO2 (M + H)
+ 224.1645,
found 224.1653.
Representative Procedure for the Synthesis of (1-(tert-
Butoxycarbonyl)-5-ethylpyrrol-2-yl)boronic Acid (69a). To a
stirred solution of 2,2,6,6-tetramethylpiperidine (2.60 g, 18.46 mmol)
in dry THF (50 mL) was added dropwise n-BuLi (1.6 M in pentane,
12.5 mL, 20.0 mmol) under an argon atmosphere at −78 °C. The
reaction mixture was allowed to warm to 0 °C and maintained at that
temperature for 30 min. After cooling again to −78 °C, a solution of
68a (3.0 g, 15.38 mmol) in THF (10 mL) was added. The reaction
mixture was stirred for 2 h at −78 °C prior to the addition of trimethyl
borate (7.92 g, 76.92 mmol). The solution was allowed to react at
ambient temperature overnight. The reaction mixture was diluted with
EtOAc (200 mL), washed with water and brine solution, and dried
over anhydrous Na2SO4. The solvent was removed by rotary evapora-
tion to furnish the desired product 69a (3.12 g, 85%) as a brown solid.
The product 69a was carried forward into the next reaction without
further puriﬁcation. The products 69b (1.82 g, 76%), 69c (1.59 g,
65%), and 69d (1.62 g, 68%) were also carried forward into the next
reaction without further puriﬁcation.
Synthesis of 32−35. Compounds 32 (403 mg, 75%), 33 (467 mg,
77%), 34 (1.59 g, 57%), and 35 (1.62 g, 55%) were synthesized by the
same procedure as described for 9.
5′-Ethyl-3,4-dimethyl-[2,2′-bipyrrole]-5-carboxaldehyde (32). 1H
NMR (DMSO-d6, 600 MHz) δ 10.99 (s, 1H), 10.94 (br s, 1H), 9.46
(s, 1H), 6.35 (br s, 1H), 5.89 (br s, 1H), 2.61 (br s, 2H), 2.22 (s, 3H),
2.06 (s, 3H), 1.21 (br s, 3H); 13C NMR (CDCl3 + DMSO-d6, 150
MHz) δ 175.0, 135.6, 131.8, 130.9, 127.5, 122.0, 115.3, 108.9, 106.0,
20.3, 13.6, 9.9, 8.9; HRMS (ESI) calcd for C13H17N2O (M + H)
+
217.1335, found 217.1348.
5′-Isobutyl-3,4-dimethyl-[2,2′-bipyrrole]-5-carboxaldehyde (33).
1H NMR (CDCl3 + DMSO-d6, 400 MHz) δ 11.18 (br s, 1H), 10.92
(br s, 1H), 9.24 (s, 1H), 6.40 (br s, 1H), 5.85 (s, 1H), 2.41 (d, J = 7.1
Hz, 2H), 2.17 (s, 3H), 2.04 (s, 3H), 1.86 (m, 1H), 0.85 (d, J = 6.4 Hz,
6H); 13C NMR (CDCl3 + DMSO-d6, 150 MHz) δ 173.6, 134.4, 134.2,
133.3, 127.5, 122.3, 116.8, 110.2, 107.9, 37.3, 29.1, 22.4 (2C), 10.3, 8.7;
HRMS (ESI) calcd for C15H21N2O (M + H)
+ 245.1648, found 245.1660.
3,3′,4,5′-Tetramethyl-[2,2′-bipyrrole]-5-carbaldehyde (34). 1H
NMR (CDCl3, 400 MHz) δ 9.52 (s, 1H), 9.24 (br s, 1H), 8.40 (br s,
1H), 5.84 (d, J = 2.6 Hz, 1H), 2.31 (s, 6H), 2.16 (s, 3H), 2.09 (s, 3H);
13C NMR (CDCl3, 100 MHz) δ 174.2, 130.4, 127.4, 127.2, 117.0,
116.7, 116.6, 107.7 (2C), 11.6, 11.1, 8.6, 7.8; HRMS (ESI) calcd for
C13H17N2O (M + H)
+ 217.1335, found 217.1348.
4′-Ethyl-3,3′,4,5′-tetramethyl-[2,2′-bipyrrole]-5-carboxaldehyde
(35). HRMS (ESI) calcd for C15H21N2O (M + H)
+ 245.1648, found
245.1656.
Synthesis of (1-(tert-Butoxycarbonyl)-4-ethyl-pyrrol-2-yl)-
boronic Acid (71). Compound 71 (1.81 g, 74%) was synthesized
by the same procedure as described for 69a. The product 71 was
carried forward into the next reaction without further puriﬁcation.
Synthesis of 4′-Ethyl-3,4-dimethyl-[2,2′-bipyrrole]-5-carbox-
aldehyde (36). Compound 36 (413 mg, 77%) was synthesized by the
same procedure as described for 9. 1H NMR (DMSO-d6, 400 MHz)
δ 11.26 (br s, 1H), 10.75 (br s, 1H), 9.48 (s, 1H), 6.70 (s, 1H), 6.35 (s,
1H), 2.45 (q, J = 7.5 Hz, 2H), 2.22 (s, 3H), 2.07 (s, 3H), 1.15 (t, J =
7.5 Hz, 3H); 13C NMR (DMSO-d6, 100 MHz) δ 173.4, 130.8, 129.8,
126.3, 125.6, 122.2, 122.0, 114.6, 107.4, 18.6, 14.0, 8.9, 7.3; HRMS
(ESI) calcd for C13H17N2O (M + H)
+ 217.1335, found 217.1346.
Synthesis of tert-Butyl 1-Formyl-4,5,6,7-tetrahydroisoindole-
2-carboxylate (72). Compound 72 (3.17 g, 95%) was synthesized
by the same procedure as described for 68a. 1H NMR (CDCl3,
400 MHz) δ 10.38 (s, 1H), 7.14 (s, 1H), 2.88 (t, J = 5.8 Hz, 2H), 2.52
(t, J = 5.6 Hz, 2H), 1.74 (m, 4H), 1.69 (s, 9H); 13C NMR (CDCl3,
100 MHz) δ 183.4, 148.7, 137.3, 129.1, 123.8, 122.7, 84.8, 28.0 (3C),
24.2, 22.7, 22.6, 21.5; HRMS (ESI) calcd for C14H19NaNO3 (M + Na)
+
272.1257, found 272.1263.
Synthesis of tert-Butyl 1-(Dimethoxymethyl)-4,5,6,7-
tetrahydroisoindole-2-carboxylate (73). A solution of aldehyde
72 (2.0 g, 8.03 mmol), trimethyl orthoformate (1.70 g, 16.06 mmol),
and a catalytic amount (30 mg) of p-toluenesulfonic acid (PTSA) in
MeOH (20 mL) was stirred at room temperature for 1 h. The reaction
mixture was diluted with Et2O (200 mL) and washed with a solution
of NaHCO3. The organic layer was washed with water and dried over
anhydrous Na2SO4. The solvent was removed by rotary evaporation
and the product was chromatographed on silica gel, with ethyl acetate/
hexanes as eluent, to aﬀord the pure product 73 (2.01 g, 85%). HRMS
(ESI) calcd for C16H26NO4 (M + H)
+ 296.1856, found 296.1863.
Synthesis of (3-Formyl-4,5,6,7-tetrahydroisoindol-1-yl)-
boronic Acid (74). To a stirred solution of 73 (1.2 g, 4.06 mmol)
in THF (10 mL) was added triisopropyl borate (1.14 g, 6.10 mmol).
The solution was cooled to 0−5 °C in an ice bath, and lithium
diisopropylamide (LDA; 2 N, 4 mL, 8.13 mmol) was added over
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20 min, and stirring was continued for an additional hour. The
saturated ammonium chloride (5 mL) and 10% aqueous potassium
bisulfate solution (50 mL) were added to adjust to pH 2, followed by
stirring at room temperature for 2 h. The reaction mixture was diluted
with EtOAc (200 mL), washed with brine solution, and dried over
anhydrous Na2SO4. The solvent was removed by rotary evaporation to
furnish the desired product 74 (738 mg, 94%) as an orange solid. The
product 74 was carried forward into the next reaction without further
puriﬁcation.
Synthesis of 3-(Imidazol-2-yl)-4,5,6,7-tetrahydroisoindole-1-
carboxaldehyde (37). Compound 37 (478 mg, 65%) was
synthesized by the same procedure as described for 9. 1H NMR
(DMSO-d6, 400 MHz) δ 12.02 (s, 1H), 11.68 (br s, 1H), 9.53 (s, 1H),
7.26 (br s, 1H), 7.07 (br s, 1H), 2.79 (m, 4H), 1.72 (m, 4H); 13C
NMR (CDCl3 + DMSO-d6, 100 MHz) δ 176.9, 139.6, 132.5, 129.3,
127.3, 126.2, 120.7, 117.2, 22.8, 22.6, 22.3, 20.9; HRMS (ESI) calcd
for C12H14N3O (M + H)
+ 216.1131, found 216.1136.
Synthesis of 1-Methyl-4,5,6,7-tetrahydroisoindole (77). To
a stirred suspension of LiAlH4 (1.57 g, 41.45 mmol) in dry THF
(50 mL) was added dropwise 53 (2.0 g, 10.36 mmol) in THF (50 mL)
at 0 °C. Then the resulting solution was stirred at the same tem-
perature for an additional 3 h and heated to reﬂux overnight. The
reaction was quenched with saturated solution of sodium sulfate. The
insoluble solid was ﬁltered oﬀ and washed with DCM (100 mL). Then
the combined organic solution was concentrated under reduced
pressure and the product was chromatographed on silica gel, with ethyl
acetate/hexanes as eluent, to aﬀord the desired product 77 (1.19 g,
85%). 1H NMR (CDCl3, 400 MHz) δ 7.61 (br s, 1H), 6.47 (d, J = 2.8
Hz, 1H), 2.71 (t, J = 5.8 Hz, 2H), 2.60 (t, J = 6.0 Hz, 2H), 1.90 (s,
3H), 1.87 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 121.9, 120.1,
115.5, 110.7, 24.2 (2C), 22.3, 21.5, 10.9; HRMS (ESI) calcd for
C9H14N (M + H)
+ 136.1121, found 136.1117.
Synthesis of 3-Methyl-4,5,6,7-tetrahydroisoindole-1-carbox-
aldehyde (38). Compound 38 (917 mg, 76%) was synthesized by the
same procedure as described for 55. 1H NMR (CDCl3, 400 MHz) δ
10.10 (br s, 1H), 9.37 (s, 1H), 2.82 (t, J = 5.8 Hz, 2H), 2.41 (t, J = 6.0
Hz, 2H), 2.23 (s, 3H), 1.78 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ
175.0, 135.4, 135.1, 126.5, 120.2, 23.3, 22.8, 21.0, 20.8, 11.3; HRMS
(ESI) calcd for C10H14NO (M + H)
+ 164.1070, found 164.1065.
Synthesis of Bis(3-ethyl-4-methyl-1H-pyrrol-2-yl)methane
(79). Compound 79 (1.13 g, 92%) was synthesized by the same
procedure as described for 54. 1H NMR (CDCl3, 400 MHz) δ 7.25
(br s, 2H), 6.26 (t, J = 1.2 Hz, 2H), 3.73 (s, 2H), 2.36 (q, J = 7.5 Hz,
4H), 1.97 (s, 6H), 1.02 (t, J = 7.5 Hz, 6H); HRMS (ESI) calcd for
C15H23N2 (M + H)
+ 231.1856, found 231.1861.
Synthesis of 5,5′-Methylenebis(4-ethyl-3-methyl-1H-pyrrole-
2-carbaldehyde) (39). Compound 39 (907 mg, 73%) was syn-
thesized by the same procedure as described for 55. 1H NMR (CDCl3,
400 MHz) δ 11.46 (br s, 2H), 9.48 (s, 2H), 3.86 (s, 2H), 2.31 (q, J =
7.4 Hz, 4H), 2.18 (s, 6H), 0.81 (t, J = 7.5 Hz, 6H); 13C NMR (CDCl3,
100 MHz) δ 176.5, 134.2, 130.0, 127.9, 123.7, 22.4, 16.3, 14.9, 8.4
(dimer); HRMS (ESI) calcd for C17H23N2O2 (M + H)
+ 287.1786,
found 287.1782.
Representative Procedure for the Synthesis of Prodiginine
(85). To a stirred solution of 6 (250 mg, 1.31 mmol) and 2,4-
dialkylpyrrole (80; 829 mg, 2.63 mmol) in anhydrous methanol
(50 mL) was added methanolic 2 N HCl (catalytic amount). The
resulting brightly colored solution was stirred for 5 h at room tem-
perature. The methanol was removed under reduced pressure and the
product was chromatographed on neutral alumina, with ethyl acetate/
hexanes as eluent, to aﬀord the desired prodiginine analogue 85·HCl
(468 mg, 68%) as a bright red compound. 1H NMR (CDCl3, 400
MHz) δ 12.85 (br s, 1H), 12.81 (br s, 1H), 12.65 (br s, 1H), 7.30 (d,
J = 8.1 Hz, 2H), 7.26 (m, 5H), 7.06 (d, J = 8.1 Hz, 2H), 7.01 (s, 1H),
6.97 (m, 1H), 6.38 (m, 1H), 6.09 (d, J = 1.9 Hz, 1H), 5.87 (d, J = 1.6
Hz, 1H), 4.23 (s, 2H), 4.00 (s, 3H), 3.93 (s, 2H); 13C NMR (CDCl3,
100 MHz) δ 166.2, 149.1, 148.8, 141.0, 138.3, 136.4, 132.5, 132.2,
130.5 (2C), 129.8 (2C), 128.7 (4C), 127.9, 123.9, 122.1, 121.7, 118.3,
113.4, 112.9, 112.2, 93.1, 58.9, 33.8, 31.9; HRMS (ESI) calcd for
C28H24Cl2N3O (M + H)
+ 488.1291, found 488.1284; IR (KBr) vmax
3320, 3010, 2845, 1510, 1045, 742 cm−1.
Synthesis of 5′-((3,5-Bis(4-chlorobenzyl)-1-methylpyrrol-2-
yl)methylene)-4′-methoxy-1-methyl-2,2′-bipyrrole (87). To a
stirred solution of prodiginine 85 (50 mg, 0.10 mmol) in DMF
(10 mL) was added NaH (10 mg, 0.41 mmol) at 0 °C. The resulting
bright red suspension was stirred for 10 min, and methyl iodide
(58 mg, 0.41 mmol) was added at 0 °C and stirred for additional
30 min. The reaction mixture was warmed to room temperature and
gradually poured into ice cold water and extracted with ethyl acetate
(3 × 30 mL). The combined organic layers were washed with water
and dried over anhydrous Na2SO4. The solvent was evaporated under
reduced pressure and the product was chromatographed on neutral
alumina, with ethyl acetate/hexanes as eluent, to aﬀord the desired
prodiginine 87 (46 mg, 85%). 1H NMR (CDCl3, 400 MHz) δ 7.24 (d,
J = 8.3 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 7.11 (d, J = 8.4 Hz, 2H),
7.06 (d, J = 8.3 Hz, 2H), 6.84 (s, 1H), 6.74 (br s, 1H), 6.68 (dd, J =
1.5, 3.8 Hz, 1H), 6.17 (dd, J = 2.6, 3.7 Hz, 1H), 5.92 (s, 1H), 5.75 (s,
1H), 4.25 (s, 2H), 3.96 (s, 3H), 3.90 (s, 3H), 3.89 (s, 2H), 3.63 (s,
3H); 13C NMR (CDCl3, 100 MHz) δ 167.8, 161.2, 142.1, 140.7,
136.9, 132.4, 131.6, 130.1 (3C), 129.8 (2C), 129.3, 128.8, 128.7 (3C),
127.8 (2C), 127.2, 115.3, 113.5, 111.7, 108.4, 96.9, 58.4, 37.5, 33.0,
32.7, 29.7; HRMS (ESI) calcd for C30H28Cl2N3O (M + H)
+ 516.1604,
found 516.1607.
Representative Procedure for the Synthesis of Tambjamine
(99). To a stirred solution of 6 (100 mg, 0.52 mmol) and n-butylamine
(77 mg, 1.05 mmol) in anhydrous methanol (10 mL) was added
methanolic 2 N HCl (catalytic amount). The resulting pale yellow
colored solution was stirred at reﬂuxing temperature for 5 h, and the
solvent was removed under reduced pressure. The crude solid was
dissolved in EtOAc (50 mL) and washed with 2 N HCl (2 × 10 mL).
The organic layer was dried over anhydrous Na2SO4. The solvent was
removed under reduced pressure and the product was chromato-
graphed on neutral alumina, with ethyl acetate/hexanes as eluent, to
aﬀord the desired tambjamine 99 (117 mg, 91%) as a yellow solid. 1H
NMR (CDCl3, 400 MHz) δ 7.26 (s, 1H), 6.98 (dd, J = 1.3, 2.7 Hz,
1H), 6.67 (dd, J = 1.3, 3.6 Hz, 1H), 6.20 (dd, J = 2.7, 3.6 Hz, 1H), 5.87
(s, 1H), 3.84 (s, 3H), 3.41 (t, J = 7.1 Hz, 2H), 1.67 (m, 2H), 1.37 (m,
2H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 163.7,
142.2, 140.3, 124.0, 122.7, 113.1, 110.8, 110.7, 91.1, 58.5, 50.7, 32.2,
19.7, 13.6; HRMS (ESI) calcd for C14H20N3O (M + H)
+ 246.1601,
found 246.1605. IR (KBr) vmax 3299, 2936, 1420, 1175, 722 cm
−1.
Representative Procedure for the Synthesis of N-(Adamantan-
1-yl)-2-(((oxoboranyl)methylene)amino)acetamide (188). To a
stirred solution of 44 (2.0 g, 11.43 mmol) in a mixture of THF
(25 mL) and CH2Cl2 (25 mL) were added 1-adamantylamine
(2.07 g, 13.71 mmol), DMAP (348 mg, 2.85 mmol), and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
(EDCl, 2.62 g, 13.71 mmol). The reaction mixture was stirred at
room temperature for 4 h. The reaction was quenched with saturated
aqueous NH4Cl solution (50 mL) and extracted with ethyl acetate
(3 × 100 mL). The combined organic phases were washed with brine
and dried over anhydrous Na2SO4. The solvent was removed under
reduced pressure and the product was chromatographed on neutral
alumina, with ethyl acetate/hexanes as eluent, to aﬀord the desired
product 188 (2.99 g, 85%). 1H NMR (CDCl3, 400 MHz) δ 6.01 (br s,
1H), 5.52 (br s, 1H), 3.64 (d, J = 4.7 Hz, 2H), 2.03 (m, 3H), 1.96 (d,
J = 2.9 Hz, 6H), 1.64 (m, 6H), 1.41 (s, 9H); HRMS (ESI) calcd for
C17H29N2O3 (M + H)
+ 309.2173, found 309.2180.
Representative Procedure for the Synthesis of N-(Adamantan-
1-yl)-2-aminoacetamide (189). Compound 188 (2.5 g, 8.11 mmol)
was dissolved in 20 mL of triﬂuoroacetic acid/water (1:1) and stirred
at room temperature for 3 h. The reaction mixture was neutralized
with 2 N NaOH and extracted with ethyl acetate (3 × 100 mL). The
combined organic layers were washed with brine and dried over
anhydrous Na2SO4. The solvent was removed under reduced pressure
to obtain the pure product 189 (1.60 g, 95%) as a white solid. 1H
NMR (CDCl3, 400 MHz) δ 6.88 (br s, 1H), 3.20 (s, 2H), 2.06 (br s,
3H), 1.97 (d, J = 2.8 Hz, 6H), 1.70 (m, 6H); HRMS (ESI) calcd for
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C12H21N2O (M + H)
+ 209.1648, found 209.1646. Note: Two NH
protons are not appearing under these conditions.
Synthesis of N-(2-((Adamantan-1-yl)amino)-2-oxoethyl)-
pyrrole-2-carboxamide (190). Compound 190 (1.09 g, 81%) was
synthesized by the same procedure as described for 188. 1H NMR
(CDCl3, 400 MHz) δ 9.83 (br s, 1H), 7.21 (t, J = 5.3 Hz 1H), 6.85 (m,
1H), 6.69 (m, 1H), 6.16 (m, 1H), 6.08 (s, 1H), 3.90 (d, J = 5.3 Hz,
2H), 1.99 (br s, 3H), 1.92 (d, J = 2.6 Hz, 6H), 1.59 (m, 6H); 13C
NMR (CDCl3 + CD3OD, 100 MHz) δ 169.1, 162.4, 124.9, 122.2,
111.2, 109.5, 51.0, 43.2, 42.2 (3C), 36.2 (3C), 29.4 (3C); HRMS
(ESI) calcd for C17H23NaN3O2 (M + Na)
+ 324.1682, found 324.1693.
Synthesis of N1-((Pyrrol-2-yl)methyl)-N2-(adamantan-1-yl)-
ethane-1,2-diamine (191). Compound 191 (186 mg, 82%) was
synthesized by the same procedure as described for 67a. 1H NMR
(CDCl3, 400 MHz) δ 9.52 (br s, 1H), 6.74 (dd, J = 1.9, 2.7 Hz, 1H),
6.11 (dd, J = 3.0, 5.6 Hz, 1H), 6.02 (d, J = 1.9 Hz, 1H), 3.80 (s, 2H),
3.00 (br s, 2H), 2.76 (m, 4H), 2.08 (br s, 3H), 1.69−1.60 (m, 12H);
13C NMR (CDCl3, 100 MHz) δ 130.1, 117.5, 107.8, 106.4, 51.5, 48.9,
46.1, 42.1 (3C), 39.4, 36.5 (3C), 29.5 (3C); HRMS (ESI) calcd for
C17H28N3 (M + H)
+ 274.2278, found 274.2287.
Synthesis of 3-(Pyrrol-2-yl)acrylic Acid Methyl Ester (192).
To a stirred suspension of NaH (910 mg, 37.89 mmol) in 50 mL of
anhydrous dimethoxyethane at 0 °C was added dropwise methyl
diethylphosphonoacetate (7.96 g, 37.89 mmol). The reaction mixture
was stirred at 0 °C for 30 min and then allowed to warm to room
temperature. Pyrrole-2-carboxaldehyde (40; 3.0 g, 31.58 mmol) was
added, and the reaction mixture was stirred for additional 4 h. The
reaction was quenched with ice−water and extracted with ethyl acetate
(3 × 50 mL). The combined organic layer was washed with brine and
dried over anhydrous Na2SO4. The solvent was evaporated under
reduced pressure and the product was chromatographed on silica gel,
with ethyl acetate/hexanes as eluent, to aﬀord the pure product 192
(3.72 g, 78%). Rf value of the product 192 is similar to the starting
material 40; the visualization of the product was black spot on TLC
after applying the iodine vapor. 1H NMR (CDCl3, 600 MHz) δ 9.26
(br s, 1H), 7.61 (d, J = 15.9 Hz, 1H), 6.94 (d, J = 1.4 Hz, 1H), 6.58 (s,
1H), 6.29 (d, J = 3.6 Hz, 1H), 6.10 (d, J = 15.9 Hz, 1H), 3.80 (s, 3H).
HRMS (ESI) calcd for C8H10NO2 (M + H)
+ 152.0706, found 152.0710.
Synthesis of 3-(Pyrrol-2-yl)acrylic Acid (193). To a stirred
suspension of 192 (2.0 g, 13.24 mmol) in a mixture of THF (50 mL)
and water (60 mL) was added LiOH·H2O (1.66 g, 39.73 mmol).
The reaction mixture was stirred at 60 °C for 12 h after which it was
cooled to 0 °C and washed with ethyl acetate (3 × 30 mL). The
aqueous layer was carefully acidiﬁed to pH 2 with 2 N HCl and
extracted with ethyl acetate (3 × 50 mL). The combined extracts
were dried over anhydrous Na2SO4 and concentrated under reduced
pressure to give the pure product 193 (1.74 g 96%). 1H NMR
(CD3OD, 600 MHz) δ 7.51 (d, J = 15.8 Hz, 1H), 6.91 (dd, J = 1.1, 2.3
Hz, 1H), 6.49 (dd, J = 1.1, 3.5 Hz, 1H), 6.18 (dd, J = 2.2, 4.9 Hz, 1H),
6.04 (d, J = 15.8 Hz, 1H); HRMS (ESI) calcd for C7H7NaNO2 (M +
Na)+ 160.0369, found 160.0363. Note: NH and COOH protons are
not appearing under these conditions.
Synthesis of N-(2-Adamantan-1-yl)amino)-2-oxoethyl)-3-
(pyrrol-2-yl)acrylamide (194). Compound 194 (2.02 g, 85%) was
synthesized by the same procedure as described for 188. 1H NMR
(DMSO-d6, 600 MHz) δ 11.34 (s, 1H), 7.95 (t, J = 5.8 Hz, 1H), 7.27
(d, J = 15.7 Hz, 1H), 7.26 (s, 1H), 6.91 (dd, J = 2.4, 3.7 Hz, 1H), 6.41
(s, 1H), 6.26 (d, J = 15.7 Hz, 1H), 6.12 (dd, J = 2.4, 5.6 Hz, 1H), 3.71
(d, J = 5.8 Hz, 2H), 1.99 (s, 3H), 1.92 (d, J = 2.7 Hz, 6H), 1.61 (m,
6H); 13C NMR (DMSO-d6, 100 MHz) δ 167.9, 165.9, 129.8, 128.5,
121.6, 114.9, 111.5, 109.5, 50.7, 42.5, 41.0 (3C), 36.0 (3C), 28.8 (3C);
HRMS (ESI) calcd for C19H25NaN3O2 (M + Na)
+ 350.1839, found
350.1853.
Representative Procedure for the Synthesis of 195. To a
stirred solution of 194 (500 mg, 1.52 mmol) in methanol (10 mL) at
room temperature was added NiCl2·6H2O (180 mg, 0.76 mmol).
When the clear solution acquired a greenish color, the whole reaction
mixture was brought to 0 °C and NaBH4 (85 mg, 2.29 mmol)
was added portionwise. The black reaction mixture was stirred for
30 min at 0 °C, and the solvent was removed under reduced pressure.
The crude product was dissolved in ethyl acetate (50 mL) and treated
with aqueous NH4Cl (2 × 10 mL). The organic layer was washed with
brine and dried over anhydrous Na2SO4. The organic solvent was
evaporated under reduced pressure and the product was chromato-
graphed on silica gel, with ethyl acetate/hexanes as eluent, to aﬀord
the desired product 195 (473 mg, 94%) as a white solid. 1H NMR
(DMSO-d6, 600 MHz) δ 11.50 (s, 1H), 7.97 (t, J = 5.8 Hz, 1H), 7.24
(s, 1H), 6.55 (dd, J = 2.3, 3.9 Hz, 1H), 5.86 (dd, J = 2.6, 5.4 Hz, 1H),
5.72 (s, 1H), 3.62 (d, J = 5.8 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 2.41 (t,
J = 7.4 Hz, 2H), 2.00 (br s, 3H), 1.91 (d, J = 2.6 Hz, 6H), 1.60 (br s,
6H); 13C NMR (DMSO-d6, 100 MHz) δ 171.8, 167.9, 130.8, 116.0,
107.0, 104.2, 50.7, 42.3, 41.0 (3C), 35.9 (3C), 35.3, 28.8 (3C), 23.2;
HRMS (ESI) calcd for C19H28N3O2 (M + H)
+ 330.2176, found
330.2169.
Synthesis of N1-(3-(Pyrrol-2-yl)propyl)-N2-(adamantan-1-yl)-
ethane-1,2-diamine (196). Compound 196 (178 mg, 78%) was
synthesized by the same procedure as described for 67a. 1H NMR
(CDCl3, 400 MHz) δ 9.28 (br s, 1H), 6.68 (s, 1H), 6.12 (t, J = 2.8 Hz,
1H), 5.92 (m, 1H), 2.78−2.66 (m, 8H), 2.16 (br s, 2H), 2.09 (br s,
3H), 1.83 (m, 2H), 1.86−1.67 (m, 12H); 13C NMR (CDCl3, 100
MHz) δ 132.1, 116.2, 107.9, 104.9, 50.1, 50.0, 48.9, 42.6 (3C), 39.6,
36.7 (3C), 29.6 (4C), 25.6; HRMS (ESI) calcd for C19H32N3 (M + H)
+
302.2591, found 302.2587.
In Vitro Antimalarial Activity: P. falciparum Growth Inhib-
ition. In vitro antimalarial activity was determined by the malaria
SYBR Green I-based ﬂuorescence (MSF) assay described previously66
with minor modiﬁcations as previously described,67 and expressed as
the compound concentration inhibiting growth by 50% (IC50).
HepG2 Cytotoxicity Assay. Drugs were dissolved in DMSO to
make 10 mM stock solutions. Human hepatocarcinoma cells (HepG2)
were maintained on RPMI-1640 medium supplemented with 10% fetal
bovine serum at 37 °C in a humidiﬁed 5% CO2 atmosphere. Cells
were seeded at a density of 2 × 104 per well in 96-well ﬂat-bottom
tissue culture plates containing complete medium in a total volume of
160 μL/well. The cells were allowed to attach at 37 °C overnight. On
the following day, drug solutions (40 μL/well) were serially diluted
with complete culture medium across the plate. The plates were then
incubated at 37 °C and 5% CO2 for another 24−36 h. Afterward, the
medium was aspirated and replaced with complete RPMI medium
(200 μL/well), and the plates were incubated for an additional 24 h at
37 °C and 5% CO2. An aliquot of a stock solution of resazurin (Alamar
Blue, prepared in 1× PBS) was then added at 20 μL per well (ﬁnal
concentration 10 μM), and the plates were returned to the incubator for
3 h. After this period, ﬂuorescence in each well, indicative of cellular
redox activity, was measured in a Gemini EM plate reader with excitation
wavelength at 560 nm and emission wavelength at 590 nm.68,69 IC50
values were determined by nonlinear regression analysis of logistic
concentration−ﬂuorescence intensity curves (GraphPad Prism software).
In Vivo Eﬃcacy against Murine Malaria. The in vivo activity of
selected PGs and TAs was assessed against the blood stages using a
modiﬁed 4-day test.71,72 The 4- to 5-week-old female CF1 mice
(Charles River Laboratories) were infected intravenously with 2.5 ×
105 P. yoelii (Kenya strain, MR4 MRA-428) parasitized erythrocytes
from a donor animal. Drug administration commenced the day after
the animals were inoculated (day 1). The test compounds were
dissolved in PEG-400 and administered by oral gavage once daily for
4 successive days; chloroquine phosphate was used as a positive
control. Blood for blood ﬁlm analysis and body weights were obtained
on the day following the last dose and then at weekly intervals through
day 28. Blood ﬁlms were Giemsa stained and examined microscopi-
cally to determine the levels of parasitemia. These blood samples were
collected from the tail vein with the aid of a syringe needle. All mice
were observed daily to assess their clinical signs, which were recorded.
Animals with observable parasitemia following the experiment were
euthanized; animals cleared of parasites from their bloodstream were
observed daily with assessment of parasitemia performed weekly until day
28, at which point we score the animal(s) as cured of infection, and the
animals were euthanized. All treated mice with a negative smear on day 28
were considered cured (100% protection). ED50 values (mg kg
−1 day−1)
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were derived graphically from the dose required to reduce parasite
burden by 50% relative to drug-free controls.
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